Biotech Showcase™ 2013 Presenting Companies

A preliminary list of presenters at Biotech Showcase™ 2013 will be published in late Fall 2012.

Biotech Showcase 2012 presenting companies

Click on any row to see more company information

2B BlackBio SL
Country: Spain

BlackBio's patented microsequencing technologies provide accuracy, robustness, speed, simplicity and affordability to nucleic acids sequencing applied to diagnostics and perso...

Share this:

2B BlackBio SL

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

BlackBio's patented microsequencing technologies provide accuracy, robustness, speed, simplicity and affordability to nucleic acids sequencing applied to diagnostics and personalized medicine. We exclusively address sequencing to the targeted nucleic acid regions of clinical interest, providing exact readouts, saving time and money in comparison to other sequencing methods.

Visit: http://www.blackbio.eu
Connect with 2B BlackBio SL on partnering360^®

Biotech Showcase™ 2013

4s3 Bioscience
Country: United States

4s3 Bioscience is developing therapies for orphan genetic muscle diseases utilizing an antibody-based targeting system capable of enhanced intracellular delivery. The company'...

Share this:

4s3 Bioscience

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

4s3 Bioscience is developing therapies for orphan genetic muscle diseases utilizing an antibody-based targeting system capable of enhanced intracellular delivery. The company's lead product candidates are muscle-protein fusions and demonstrated in vivo POC now validates the potential for multiple platform opportunities in the field of muscular dystrophies and enzyme-deficiency disorders.
Connect with 4s3 Bioscience on partnering360^®

Biotech Showcase™ 2013

Aastrom Biosciences
(NASDAQ:ASTM)

Aastrom is committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

Share this:

Aastrom Biosciences

Track: Regenerative Medicine
Ownership: Public
Ticker: ASTM
Stock exchange: NASDAQ
Schedule information will be posted soon

Aastrom is committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

Visit: http://www.aastrom.com/
Connect with Aastrom Biosciences on partnering360^®

Biotech Showcase™ 2013

ActoGeniX NV
Country: Belgium

ActoGeniX is developing a novel generation of biological drugs, ActoBiotics™, which are orally administered and aimed at treating gastrointestinal, mucosal, and immunologica...

Share this:

ActoGeniX NV

Track: Private
Country: Belgium
Ownership: Private
Schedule information will be posted soon

ActoGeniX is developing a novel generation of biological drugs, ActoBiotics™, which are orally administered and aimed at treating gastrointestinal, mucosal, and immunological diseases. ActoGeniX is in Series B fundraising to fund the phase IIB study of its lead product AG013. Current investors are GIMV, LSP, Ventech, Aescap, and Biovest.

Visit: http://www.actogenix.com
Connect with ActoGeniX NV on partnering360^®

Biotech Showcase™ 2013

Adaptimmune Ltd.
Country: United Kingdom

Adaptimmune’s mission is to take so-called "adoptive T cell therapy" to the next level by leveraging its expertise in engineering high affinity T cell receptor proteins (TCR...

Share this:

Adaptimmune Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Adaptimmune’s mission is to take so-called "adoptive T cell therapy" to the next level by leveraging its expertise in engineering high affinity T cell receptor proteins (TCRs) as a means of "supercharging" the strength of patient T cell responses and is in the clinic with multiple TCRs in multiple indications

Visit: http://www.adaptimmune.com
Connect with Adaptimmune Ltd. on partnering360^®

Biotech Showcase™ 2013

Addex Pharmaceuticals
(SWX:ADXN)
Country: Switzerland

Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer s...

Share this:

Addex Pharmaceuticals

Track: Public
Country: Switzerland
Ownership: Public
IPO: 2007
Ticker: ADXN
Stock exchange: SWX
Main sector: Biotechnology - Therapeutics
Subsector: Small molecules
Founded: 2002
Employees: 86
Schedule information will be posted soon

Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs.

Visit: http://www.addexpharma.com
Connect with Addex Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

ADOCIA
Country: France

Adocia is specialized in the design of innovative protein formulation with its BioChaperone® proprietary platform for enhancing therapeutic proteins efficacy. Two products ha...

Share this:

ADOCIA

Track: Private
Country: France
Ownership: Private
Schedule information will be posted soon

Adocia is specialized in the design of innovative protein formulation with its BioChaperone® proprietary platform for enhancing therapeutic proteins efficacy. Two products have been successfully tested in phase II clinical trials, HinsBet, a BioChaperone human insulin formulation as fast as insulin analogs and BioChaperone PDGF, a spray for diabetic foot ulcer.

Visit: http://www.adocia.com
Connect with ADOCIA on partnering360^®

Biotech Showcase™ 2013

Advanced Cell Technology, Inc
(OTCBB:ACTC)
Country: United States

Advanced Cell Technology applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring pat...

Share this:

Advanced Cell Technology, Inc

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: ACTC
Stock exchange: OTCBB
Schedule information will be posted soon

Advanced Cell Technology applies stem cell-based technologies (both adult and human embryonic) and other proprietary methods in the field of regenerative medicine to bring patient-specific therapies from the lab to the bedside. ACT has developed three cellular product platforms based on ground-breaking stem cell technology.

Visit: http://www.advancedcell.com
Connect with Advanced Cell Technology, Inc on partnering360^®

Biotech Showcase™ 2013

Advancell
Country: Spain

Advancell proposes a EUR 10-12 million investment opportunity for developing an oncology pipeline with two clinical stage products, one in leukemia indications (CLL, MM, MCL, ...

Share this:

Advancell

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Advancell proposes a EUR 10-12 million investment opportunity for developing an oncology pipeline with two clinical stage products, one in leukemia indications (CLL, MM, MCL, etc.) and the other in cancer supportive care (hand foot syndrome), to a significant value inflection point with potential exit in 2015.

Visit: http://www.advancell.net
Connect with Advancell on partnering360^®

Biotech Showcase™ 2013

AdvanDx
Country: United States

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. The rap...

Share this:

AdvanDx

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. The rapid results help clinicians optimize antibiotic therapy earlier in order to improve patient care and outcomes while limiting unnecessary antibiotic use and reducing cost.

Visit: http://www.advandx.com
Connect with AdvanDx on partnering360^®

Biotech Showcase™ 2013

Aethlon Medical
(OTCBB:AEMD)
Country: United States

Aethlon Medical's pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a device being develo...

Share this:

Aethlon Medical

Track: Public
Country: United States
Ownership: Public
Ticker: AEMD
Stock exchange: OTCBB
Schedule information will be posted soon

Aethlon Medical's pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a device being developed under a contract with DARPA that would reduce the incidence of sepsis in combat-injured soldiers and civilians.

Visit: http://www.aethlonmedical.com
Connect with Aethlon Medical on partnering360^®

Biotech Showcase™ 2013

Affimed Therapeutics AG
Country: Germany

Affimed is a clinical stage company developing RECRUIT-TandAb antibodies as novel and improved treatments in ONCOLOGY. The lead product AFM13 is currently being investigated i...

Share this:

Affimed Therapeutics AG

Track: Private
Country: Germany
Ownership: Private
Schedule information will be posted soon

Affimed is a clinical stage company developing RECRUIT-TandAb antibodies as novel and improved treatments in ONCOLOGY. The lead product AFM13 is currently being investigated in Phase I/IIa trials in Hodgkin Lymphoma patients. Affimed has raised USD 55 million since 2007 and is backed by a peer group of investors.

Visit: http://www.affimed.com/
Connect with Affimed Therapeutics AG on partnering360^®

Biotech Showcase™ 2013

AiroMedica LLC
Country: United States

Share this:

AiroMedica LLC

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

No information entered
Connect with AiroMedica LLC on partnering360^®

Biotech Showcase™ 2013

Aldagen
Country: United States

Aldagen is a clinical-stage company developing proprietary regenerative cell therapies. Product candidates consist of a specific population of a patient’s own stem cells, wh...

Share this:

Aldagen

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

Aldagen is a clinical-stage company developing proprietary regenerative cell therapies. Product candidates consist of a specific population of a patient’s own stem cells, which are isolated using proprietary technology and which has the potential to promote the regeneration of multiple types of cells and tissues, including the growth of new blood vessels.

Visit: http://www.aldagen.com
Connect with Aldagen on partnering360^®

Biotech Showcase™ 2013

ALEthia Biotherapeutics
Country: Canada

Alethia Biotherapeutics is capitalizing on its patented discovery technology to identify proprietary disease-specific targets and corresponding monoclonal antibodies. The curr...

Share this:

ALEthia Biotherapeutics

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

Alethia Biotherapeutics is capitalizing on its patented discovery technology to identify proprietary disease-specific targets and corresponding monoclonal antibodies. The current development focus is on moving mAbs for treating cancer induced bone loss related indications to the clinic. The company has programs addressing cancer-associated epithelial-to-mesenchymal transition and ovarian cancer.

Visit: http://www.alethiabio.com
Connect with ALEthia Biotherapeutics on partnering360^®

Biotech Showcase™ 2013

Allara Therapeutics, Inc.
Country: United States

Allara Therapeutics is a clinical stage therapeutic antibody company spinning out of Cephalon/Teva. CEP-37250/KHK2804, currently in phase I trials, targets a novel colorectal ...

Share this:

Allara Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Allara Therapeutics is a clinical stage therapeutic antibody company spinning out of Cephalon/Teva. CEP-37250/KHK2804, currently in phase I trials, targets a novel colorectal cancer antigen. Two other product candidates targeting inflammation will enter clinical development in 2012 and 2013. All products were discovered using Allara’s proven proprietary antibody engineering technologies.

Visit: http://www.allara.com
Connect with Allara Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

AlloCure
Country: United States

AlloCure, focused on cell therapy for the treatment of kidney disease, has a unique technology that allows for the isolation and expansion of a specific population of mesenchy...

Share this:

AlloCure

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

AlloCure, focused on cell therapy for the treatment of kidney disease, has a unique technology that allows for the isolation and expansion of a specific population of mesenchymal stems cells from bone marrow donation which are not recognized by the immune system allowing administration to any patient in need.

Visit: http://www.allocure.com
Connect with AlloCure on partnering360^®

Biotech Showcase™ 2013

AlphaCore Pharma
Country: United States

AlphaCore Pharma’s ACP-501 (recombinant human LCAT) is under development to regress atherosclerosis (ACS, PVD & familial hypercholesterolemia) and to treat familial LCAT def...

Share this:

AlphaCore Pharma

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

AlphaCore Pharma’s ACP-501 (recombinant human LCAT) is under development to regress atherosclerosis (ACS, PVD & familial hypercholesterolemia) and to treat familial LCAT deficiency (an orphan designated enzyme replacement therapy).

Visit: http://www.alphacorepharma.com
Connect with AlphaCore Pharma on partnering360^®

Biotech Showcase™ 2013

AlphaVax
Country: United States

AlphaVax is a development company with one of the broadest pipelines in the cancer immunotherapy space. Our vaccines have been evaluated across a number of trials in hundreds ...

Share this:

AlphaVax

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

AlphaVax is a development company with one of the broadest pipelines in the cancer immunotherapy space. Our vaccines have been evaluated across a number of trials in hundreds of patients. In all cases we demonstrated a consistently favorable safety and efficacy profile along with the ability to break self-tolerance.

Visit: http://www.alphavax.com
Connect with AlphaVax on partnering360^®

Biotech Showcase™ 2013

Anchor Therapeutics
Country: United States

Anchor Therapeutics designs and develops novel allosteric modulators that provide a solution to GPCR drug discovery and development. Anchor uses a proprietary sequence-based a...

Share this:

Anchor Therapeutics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Anchor Therapeutics designs and develops novel allosteric modulators that provide a solution to GPCR drug discovery and development. Anchor uses a proprietary sequence-based approach that targets the intracellular GPCR signaling interface, resulting in tunable allosteric modulators with robust pharmacology that can be used as both research tools and therapeutics.

Visit: http://www.anchortx.com
Connect with Anchor Therapeutics on partnering360^®

Biotech Showcase™ 2013

Anergis SA
Country: Switzerland

Anergis is developing breakthrough allergy vaccines. It raised USD 20 million in 2011 for developing its vaccine against birch pollen allergies and is raising now USD 10 mil...

Share this:

Anergis SA

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Anergis is developing breakthrough allergy vaccines. It raised USD 20 million in 2011 for developing its vaccine against birch pollen allergies and is raising now USD 10 million to accelerate the development of its vaccine against ragweed allergies, a disease affecting 20 million American people.

Visit: http://www.anergis.ch
Connect with Anergis SA on partnering360^®

Biotech Showcase™ 2013

Applied Immune Technologies
Country: Israel

AIT’s value lies in the ability to identify novel intracellularly derived, disease-specific targets and to generate therapeutic TCRL antibodies against these targets. Our un...

Share this:

Applied Immune Technologies

Track: Private
Country: Israel
Ownership: Private
Schedule information will be posted soon

AIT’s value lies in the ability to identify novel intracellularly derived, disease-specific targets and to generate therapeutic TCRL antibodies against these targets. Our unique targets represent an untapped source of cancer markers, are more abundant than extracellular proteins, and will expand the field of therapeutics antibodies beyond its current limits.

Visit: http://www.tcrl.co.il
Connect with Applied Immune Technologies on partnering360^®

Biotech Showcase™ 2013

Apricus Biosciences, Inc.
(NASDAQ:APRI)
Country: United States

Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Reve...

Share this:

Apricus Biosciences, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: APRI
Stock exchange: NASDAQ
Schedule information will be posted soon

Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the company’s commercial products and out-licensing in certain territories of its product pipeline and NexACT® technology.

Visit: http://www.apricusbio.com
Connect with Apricus Biosciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Aquapharm Biodiscovery Ltd.
Country: United Kingdom

Aquapharm discovers new drugs from marine microorganisms addressing areas of high unmet medical need including novel antibiotics, anti-fungals and second-generation oral antio...

Share this:

Aquapharm Biodiscovery Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Aquapharm discovers new drugs from marine microorganisms addressing areas of high unmet medical need including novel antibiotics, anti-fungals and second-generation oral antioxidant inflammation modulators (AIMs). Initial mining has confirmed that Aquapharm’s collection is a rich source of novel compounds with potent selective activity against these + many other pharmaceutical targets.

Visit: http://www.aquapharm.co.uk
Connect with Aquapharm Biodiscovery Ltd. on partnering360^®

Biotech Showcase™ 2013

Aradigm Corporation
(OTCBB:ARDM)
Country: United States

Aradigm is preparing to enter Phase III with its long acting inhaled antibiotic Pulmaquin™ in patients with bronchiectasis – a debilitating orphan disease condition. Aradi...

Share this:

Aradigm Corporation

Track: Public
Country: United States
Ownership: Public
Ticker: ARDM
Stock exchange: OTCBB
Schedule information will be posted soon

Aradigm is preparing to enter Phase III with its long acting inhaled antibiotic Pulmaquin™ in patients with bronchiectasis – a debilitating orphan disease condition. Aradigm also has unique human data showing profound rapid and prolonged reduction of craving for cigarettes after a single breath from Aradigm’s pure nicotine inhaler.

Visit: http://www.aradigm.com
Connect with Aradigm Corporation on partnering360^®

Biotech Showcase™ 2013

Arcion Therapeutics, Inc.
Country: United States

Arcion has two pipeline products in development for the treatment of neuropathic pain. The lead product, ARC-4558, is a 0.1% gel formulation of clonidine for topical administr...

Share this:

Arcion Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Arcion has two pipeline products in development for the treatment of neuropathic pain. The lead product, ARC-4558, is a 0.1% gel formulation of clonidine for topical administration, and is entering phase 3. We are raising USD 15 million in a series B round which will include present investors, InterWest and CMEA.

Visit: http://www.arciontherapeutics.com
Connect with Arcion Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Asmacure Ltee
Country: Canada

Asmacure Ltée is focused on the development of nicotinic receptor agonists for the treatment of inflammatory diseases.

Share this:

Asmacure Ltee

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

Asmacure Ltée is focused on the development of nicotinic receptor agonists for the treatment of inflammatory diseases.

Visit: http://www.asmacure.com
Connect with Asmacure Ltee on partnering360^®

Biotech Showcase™ 2013

AssureRx Health, Inc.
Country: United States

AssureRx is a personalized medicine company providing clinically-relevant information to help physicians select the right drug and dose for individual patients. AssureRx was ...

Share this:

AssureRx Health, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

AssureRx is a personalized medicine company providing clinically-relevant information to help physicians select the right drug and dose for individual patients. AssureRx was formed to commercialize pharmacogenomic technology from Mayo Clinic and Cincinnati Children’s Hospital targeted to patients with neuropsychiatric disorders with the goal of patient treatment outcomes at reduced cost.

Visit: http://www.assurerxhealth.com
Connect with AssureRx Health, Inc. on partnering360^®

Biotech Showcase™ 2013

Astex Pharmaceuticals
(NASDAQ:ASTX)
Country: United States

Astex is dedicated to the discovery and development of novel therapeutics with a focus on oncology. It is developing a proprietary pipeline of novel therapies and is creatin...

Share this:

Astex Pharmaceuticals

Track: Public
Country: United States
Ownership: Public
Ticker: ASTX
Stock exchange: NASDAQ
Schedule information will be posted soon

Astex is dedicated to the discovery and development of novel therapeutics with a focus on oncology. It is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.

Visit: http://www.astx.com
Connect with Astex Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Athersys, Inc.
(NASDAQ:ATHX)
Country: United States

Athersys is a clinical stage biotechnology company developing MultiStem®, a proprietary, adult-derived "off-the-shelf" stem cell product platform for multiple disease indicat...

Share this:

Athersys, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: ATHX
Stock exchange: NASDAQ
Schedule information will be posted soon

Athersys is a clinical stage biotechnology company developing MultiStem®, a proprietary, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications and areas, including cardiovascular, neurological, inflammatory and immunological conditions. MultiStem cell therapy provides benefit through multiple mechanisms of action, unlike traditional pharmaceuticals and biologics, and represents a new therapeutic modality.

Visit: http://www.athersys.com
Connect with Athersys, Inc. on partnering360^®

Biotech Showcase™ 2013

Atossa Genetics
Country: United States

Atossa is engaged in the commercialization of an FDA-cleared screening test for breast cancer. The FDA has indicated that the device can be used with cytology to “differenti...

Share this:

Atossa Genetics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Atossa is engaged in the commercialization of an FDA-cleared screening test for breast cancer. The FDA has indicated that the device can be used with cytology to “differentiate normal versus premalignant versus malignant” changes. Atossa intends to launch the product in 2011.

Visit: http://www.atossagenetics.com
Connect with Atossa Genetics on partnering360^®

Biotech Showcase™ 2013

Ausio Pharmaceuticals LLC
Country: United States

Ausio Pharmaceuticals is focused on the development of medicines for the aging population. Its lead compound is AUS-131, an estrogen receptor β agonist. The company is se...

Share this:

Ausio Pharmaceuticals LLC

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Ausio Pharmaceuticals is focused on the development of medicines for the aging population. Its lead compound is AUS-131, an estrogen receptor β agonist. The company is seeking USD 20 million to fund three Phase IIb studies. Ausio has been funded (USD 24.5 million to date) by Sanitarium Health & Wellbeing, Sydney, Australia.

Visit: http://www.ausiopharma.com
Connect with Ausio Pharmaceuticals LLC on partnering360^®

Biotech Showcase™ 2013

AVAX Technologies, Inc
(OTCBB:AVXT)
Country: United States

Share this:

AVAX Technologies, Inc

Track: Public
Country: United States
Ownership: Public
Ticker: AVXT
Stock exchange: OTCBB
Schedule information will be posted soon

No information entered

Biotech Showcase™ 2013

Avaxia Biologics
Country: United States

Avaxia Biologics is developing oral antibody therapeutics designed to work locally in the GI tract. Avaxia is leveraging USD 4.3 million in non-dilutive financing to develop a...

Share this:

Avaxia Biologics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Avaxia Biologics is developing oral antibody therapeutics designed to work locally in the GI tract. Avaxia is leveraging USD 4.3 million in non-dilutive financing to develop an oral anti-TNF antibody for inflammatory bowel disease and GI acute radiation syndrome. A Phase Ib trial for the IBDproduct will start in Q3 2012.

Visit: http://www.avaxiabiologics.com
Connect with Avaxia Biologics on partnering360^®

Biotech Showcase™ 2013

Axial Biotech
Country: United States

Axial Biotech’s mission is to deliver breakthrough diagnostics that improve and personalize the treatment of spine disorders. Axial has commercialized the ScoliScore™ AIS ...

Share this:

Axial Biotech

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Axial Biotech’s mission is to deliver breakthrough diagnostics that improve and personalize the treatment of spine disorders. Axial has commercialized the ScoliScore™ AIS Prognostic Test, a clinically validated assay that determines curve progression risk for children diagnosed with Idiopathic Scoliosis. ScoliScore provides clinically actionable information that improves patient outcomes.

Visit: http://www.axialbiotech.com/
Connect with Axial Biotech on partnering360^®

Biotech Showcase™ 2013

AxoGen, Inc.
Country: United States

AxoGen is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. AxoGen is bringing th...

Share this:

AxoGen, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

AxoGen is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft, AxoGuard® Nerve Connector, and AxoGuard® Nerve Protector.

Visit: http://www.axogeninc.com
Connect with AxoGen, Inc. on partnering360^®

Biotech Showcase™ 2013

Bio-Path Holdings, Inc.
(OTCBB:BPTH)
Country: United States

Bio-Path has developed a liposomal delivery technology for nucleic acid cancer drugs. Lead compound Liposomal Grb-2 is in a Phase I study for blood cancers. The first cohort o...

Share this:

Bio-Path Holdings, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: BPTH
Stock exchange: OTCBB
Schedule information will be posted soon

Bio-Path has developed a liposomal delivery technology for nucleic acid cancer drugs. Lead compound Liposomal Grb-2 is in a Phase I study for blood cancers. The first cohort of the trial has been completed and the drug was well tolerated with some level of anti-leukemia activity demonstrated at the low initial dose.

Visit: http://www.biopathholdings.com
Connect with Bio-Path Holdings, Inc. on partnering360^®

Biotech Showcase™ 2013

BioBDx
Country: United States

BioBehavioral Diagnostics Company manufactures and markets the Quotient™ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. The firm is...

Share this:

BioBDx

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

BioBehavioral Diagnostics Company manufactures and markets the Quotient™ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. The firm is dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.

Visit: http://www.biobdx.com/
Connect with BioBDx on partnering360^®

Biotech Showcase™ 2013

Biodesix
Country: United States

Biodesix is advancing personalized patient care by providing clinicians with accurate and important information relating to a patient’s diagnosis, prognosis, or response to ...

Share this:

Biodesix

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Biodesix is advancing personalized patient care by providing clinicians with accurate and important information relating to a patient’s diagnosis, prognosis, or response to a specific therapy. We work with research scientists, clinicians, and biotech and pharmaceutical companies to discover clinically valuable tests based on a patient’s unique molecular phenotype.

Visit: http://www.biodesix.com/
Connect with Biodesix on partnering360^®

Biotech Showcase™ 2013

Biomay AG
Country: Austria

BIOMAY AG is a clinical stage biopharmaceutical company developing disease modifying immunotherapeutics for allergies. Our first in class recombinant vaccines based on cutting...

Share this:

Biomay AG

Track: Private
Country: Austria
Ownership: Private
Schedule information will be posted soon

BIOMAY AG is a clinical stage biopharmaceutical company developing disease modifying immunotherapeutics for allergies. Our first in class recombinant vaccines based on cutting edge scientific understanding of the disease process will offer long term cure for patients and have the potential for treatment paradigm change in this important field.

Visit: http://www.biomay.com
Connect with Biomay AG on partnering360^®

Biotech Showcase™ 2013

Bioneer Corp.
(KOSDAQ:64,550)
Country: South Korea

Bioneer’s mission is Innovation, Value, Discovery in the field of oligonucleotide-based therapeutics, diagnostics and tools for drug development by applying its core compete...

Share this:

Bioneer Corp.

Track: Public
Country: South Korea
Ownership: Public
Ticker: 64,550
Stock exchange: KOSDAQ
Schedule information will be posted soon

Bioneer’s mission is Innovation, Value, Discovery in the field of oligonucleotide-based therapeutics, diagnostics and tools for drug development by applying its core competencies in molecular biology, DNA/RNA synthesis and instrument technology.

Visit: http://www.bioneer.com/
Connect with Bioneer Corp. on partnering360^®

Biotech Showcase™ 2013

Bionomics Ltd.
(ASX:BNO)
Country: Australia

Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS).

Share this:

Bionomics Ltd.

Track: Public
Country: Australia
Ownership: Public
Ticker: BNO
Stock exchange: ASX
Schedule information will be posted soon

Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS).

Visit: http://www.bionomics.com.au
Connect with Bionomics Ltd. on partnering360^®

Biotech Showcase™ 2013

Biotica Technology Ltd.
Country: United Kingdom

Biotica’s pipeline of polyketide therapeutics includes BC556, the best-in-class cyclophilin inhibitor for HCV. BC556 is the only credible alternative to a ‘nuke’ polymer...

Share this:

Biotica Technology Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Biotica’s pipeline of polyketide therapeutics includes BC556, the best-in-class cyclophilin inhibitor for HCV. BC556 is the only credible alternative to a ‘nuke’ polymerase inhibitor as the high-barrier-to-resistance component of a pan-genotype cocktail therapy. BC556 will complete clinical PoC by end-2013, in preparation for clinical combination studies in 2014.

Visit: http://www.biotica.com
Connect with Biotica Technology Ltd. on partnering360^®

Biotech Showcase™ 2013

Biotron Ltd.
(ASX:BIT)
Country: Australia

Biotron is developing novel small molecule therapeutics for treatment of Hepatitis C (HCV) and HIV. Lead drug BIT225 is a first-in-class viroporin inhibitor that has shown goo...

Share this:

Biotron Ltd.

Track: Public
Country: Australia
Ownership: Public
Ticker: BIT
Stock exchange: ASX
Schedule information will be posted soon

Biotron is developing novel small molecule therapeutics for treatment of Hepatitis C (HCV) and HIV. Lead drug BIT225 is a first-in-class viroporin inhibitor that has shown good and dose-dependent activity against HCV in a recent Phase IIa trial. It also targets HIV reservoirs, with a Phase Ib trial currently in progress.

Visit: http://www.biotron.com.au
Connect with Biotron Ltd. on partnering360^®

Biotech Showcase™ 2013

Cardium Therapeutics
(AMEX:CXM)
Country: United States

Cardium’s medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes its commercial product Excellagen™ topical gel for wound...

Share this:

Cardium Therapeutics

Track: Public
Country: United States
Ownership: Public
Ticker: CXM
Stock exchange: AMEX
Schedule information will be posted soon

Cardium’s medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes its commercial product Excellagen™ topical gel for wound care management and its clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.

Visit: http://www.cardiumthx.com
Connect with Cardium Therapeutics on partnering360^®

Biotech Showcase™ 2013

Cardoz AB
Country: Sweden

Cardoz is developing an innate specific immunomodulator with a new unique target for cardiovascular inflammation. The project is in phase IIb for abdominal aortic aneurysm, an...

Share this:

Cardoz AB

Track: Private
Country: Sweden
Ownership: Private
Schedule information will be posted soon

Cardoz is developing an innate specific immunomodulator with a new unique target for cardiovascular inflammation. The project is in phase IIb for abdominal aortic aneurysm, an overlooked EUR 1 billion market opportunity, with a potential to expand into coronary artery disease and type II diabetes.

Visit: http://www.cardoz.com/
Connect with Cardoz AB on partnering360^®

Biotech Showcase™ 2013

CD Diagnostics
Country: United States

CD Diagnostics has developed and patented a technology that enables definitive diagnosis of the source of joint pain. Our line of immunoassays detect biomarkers in synovial f...

Share this:

CD Diagnostics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

CD Diagnostics has developed and patented a technology that enables definitive diagnosis of the source of joint pain. Our line of immunoassays detect biomarkers in synovial fluid to provide more rapid, accurate and cost-effective diagnostic tools than existing technology. Disease states detected include infection, gout and rheumatoid arthritis.

Visit: http://www.cddiagnostics.com
Connect with CD Diagnostics on partnering360^®

Biotech Showcase™ 2013

CeNeRx BioPharma
Country: United States

CeNeRx BioPharma, innovator in CNS treatments, is advancing TriRima™ (phase IIb), the first monotherapy for treatment resistant depression. CeNeRx is also developing Ayrene�...

Share this:

CeNeRx BioPharma

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

CeNeRx BioPharma, innovator in CNS treatments, is advancing TriRima™ (phase IIb), the first monotherapy for treatment resistant depression. CeNeRx is also developing Ayrene™ (PII) for anxiety; a phase II small molecule (CXB909) which potentiates neurotrophic growth factor to treat neurodegenerative disorders; and selective cannabinoid compounds for pain, glaucoma and spasticity.

Visit: http://www.cenerx.com
Connect with CeNeRx BioPharma on partnering360^®

Biotech Showcase™ 2013

Cerecor, Inc.
Country: United States

Cerecor is focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human brain. Our mission is to ...

Share this:

Cerecor, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Cerecor is focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human brain. Our mission is to commercialize neuroscience discoveries at Johns Hopkins Medical Institutes ("JHMI") and our founders include world class and highly successful biotechnology investors, scientists and operational experts.

Visit: http://www.cerecor.com
Connect with Cerecor, Inc. on partnering360^®

Biotech Showcase™ 2013

Chembio Diagnostics, Inc.
(PINK:CEMI)
Country: United States

Chembio Diagnostic Systems, Inc. (OTCQB: CEMI) is a profitable microcap company that develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests for the ...

Share this:

Chembio Diagnostics, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CEMI
Stock exchange: PINK
Schedule information will be posted soon

Chembio Diagnostic Systems, Inc. (OTCQB: CEMI) is a profitable microcap company that develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests for the detection of infectious diseases globally. Chembio’s revenues have grown at a compounded average annual growth rate of 33% from 2006 to 2010 when revenues approached $17 million.

Visit: http://www.chembio.com
Connect with Chembio Diagnostics, Inc. on partnering360^®

Biotech Showcase™ 2013

ChromaDex, Inc.
(OTCBB:CDXC)
Country: United States

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, skin care, a...

Share this:

ChromaDex, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CDXC
Stock exchange: OTCBB
Schedule information will be posted soon

ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, skin care, and pharmaceutical industries. At an inflection point, ChromaDex is making the leap from research and QA services to an innovative commercial business providing health-oriented offerings to consumers and industries.

Visit: http://www.chromadex.com
Connect with ChromaDex, Inc. on partnering360^®

Biotech Showcase™ 2013

Circadian Technologies Ltd.
(ASX:CIR)
Country: Australia

Circadian is a clinical stage company developing antibody therapeutics to treat cancer and front of the eye disease based on inhibiting the angiogenic and lymphangiogenic mole...

Share this:

Circadian Technologies Ltd.

Track: Public
Country: Australia
Ownership: Public
Ticker: CIR
Stock exchange: ASX
Schedule information will be posted soon

Circadian is a clinical stage company developing antibody therapeutics to treat cancer and front of the eye disease based on inhibiting the angiogenic and lymphangiogenic molecules VEGF-C, VEGF-D and VEGFR-3. Circadian has a market cap of approximately USD 20 million, with cash and investments of >USD 20 million and significant therapeutic and diagnostic development assets.

Visit: http://www.circadian.com.au
Connect with Circadian Technologies Ltd. on partnering360^®

Biotech Showcase™ 2013

Cognition Therapeutics, Inc.
Country: United States

Cognition Therapeutics (CogRx) is a CNS drug discovery company developing proprietary and biologically-relevant screening platforms to closely model the pathology of neurodege...

Share this:

Cognition Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Cognition Therapeutics (CogRx) is a CNS drug discovery company developing proprietary and biologically-relevant screening platforms to closely model the pathology of neurodegenerative diseases. CogRx’s platforms have generated first-in-class small molecule therapeutics that block the action of the toxic soluble oligomer proteins that cause the cognitive decline associated with Alzheimer's disease.

Visit: http://www.cogrx.com

Biotech Showcase™ 2013

Colby Pharma
Country: United States

Colby is clinically developing immuno-activating anti-cancer drugs. The team has significant experience, sold two clinical drugs (2011) and one late-preclinical candidate (201...

Share this:

Colby Pharma

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Colby is clinically developing immuno-activating anti-cancer drugs. The team has significant experience, sold two clinical drugs (2011) and one late-preclinical candidate (2010). Colby develops NCEs from proprietary techplatforms. In 2H2011 Colby in-licensed JVRS-100 immuno-activators, focused product development on cancer, conducting a Ph2 Acute Myelogenous Leukemia clinical trial.

Visit: http://www.colbypharma.com
Connect with Colby Pharma on partnering360^®

Biotech Showcase™ 2013

CoLucid Pharmaceuticals, Inc.
Country: United States

CoLucid Pharmaceuticals is developing innovative therapies for the treatment of CNS disorders. CoLucid's investigational drug lasmiditan is a first-in-class Neurally Acting An...

Share this:

CoLucid Pharmaceuticals, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

CoLucid Pharmaceuticals is developing innovative therapies for the treatment of CNS disorders. CoLucid's investigational drug lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies.

Visit: http://www.colucid.com
Connect with CoLucid Pharmaceuticals, Inc. on partnering360^®

Biotech Showcase™ 2013

Complexa, Inc.
Country: United States

Complexa applies endogenous Nitro-Fatty-Acid anti-inflammatory technology to treat unmet diseases of the kidney. CXA-10’s lead indication is hospital based Contrast Induced ...

Share this:

Complexa, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Complexa applies endogenous Nitro-Fatty-Acid anti-inflammatory technology to treat unmet diseases of the kidney. CXA-10’s lead indication is hospital based Contrast Induced Nephropathy for which there is currently no effective treatment. Sales projections are over USD 650 million. Technology comparables have partnered with deal valuations up to USD 1 billion.

Visit: http://www.complexarx.com
Connect with Complexa, Inc. on partnering360^®

Biotech Showcase™ 2013

Coronado Biosciences, Inc.
(NASDAQ:CNDO)
Country: United States

Coronado Biosciences is engaged in the development of novel immunotherapy biologics. The Company’s product candidates in clinical development are: CNDO-201, a treatment of ...

Share this:

Coronado Biosciences, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CNDO
Stock exchange: NASDAQ
Schedule information will be posted soon

Coronado Biosciences is engaged in the development of novel immunotherapy biologics. The Company’s product candidates in clinical development are: CNDO-201, a treatment of autoimmune diseases, such as Crohn’s, ulcerative colitis and multiple sclerosis; and CNDO-109, which activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.

Visit: http://www.coronadobiosciences.com
Connect with Coronado Biosciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Coronado Biosciences, Inc.
(NASDAQ:CNDO)
Country: United States

Coronado Biosciences is engaged in the development of novel immunotherapy biologics. The Company’s product candidates in clinical development are: CNDO-201, a treatment of ...

Share this:

Coronado Biosciences, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CNDO
Stock exchange: NASDAQ
Schedule information will be posted soon

Visit: http://www.coronadobiosciences.com
Connect with Coronado Biosciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Cortical Dynamics Ltd.
(ASX:CDZ)
Country: Australia

The BAR monitor is a revolutionary technology which, being physiologically based, is able to detect anaesthetic and analgesic drug action on higher brain function. The BAR's p...

Share this:

Cortical Dynamics Ltd.

Track: Public
Country: Australia
Ownership: Public
Ticker: CDZ
Stock exchange: ASX
Schedule information will be posted soon

The BAR monitor is a revolutionary technology which, being physiologically based, is able to detect anaesthetic and analgesic drug action on higher brain function. The BAR's patented technology goes beyond anaesthesia monitoring and has applications in other EEG based markets, such as Neuro-diagnostic, drug-discovery, and Brain Computer Interface (BCI) technology.

Visit: http://www.corticaldynamics.com
Connect with Cortical Dynamics Ltd. on partnering360^®

Biotech Showcase™ 2013

Covagen AG
Country: Switzerland

Covagen pioneers the development of Fynomer binding proteins as next generation protein drugs for the treatment of inflammatory diseases and cancer. Covagen's drug candidate i...

Share this:

Covagen AG

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Covagen pioneers the development of Fynomer binding proteins as next generation protein drugs for the treatment of inflammatory diseases and cancer. Covagen's drug candidate is a bispecific antibody inhibiting TNF and IL-17A. Investors are Novartis Venture Funds, MP Healthcare Venture Management, Rothschild Investment Partners, Ventech and Seroba Kernel.

Visit: http://www.covagen.com
Connect with Covagen AG on partnering360^®

Biotech Showcase™ 2013

Cristal Delivery
Country: Netherlands

Cristal Delivery created value by building a limited portfolio of innovative nanomedicines. Commercialization will take place by out-licensing products to late-stage pharmaceu...

Share this:

Cristal Delivery

Track: Private
Country: Netherlands
Ownership: Private
Schedule information will be posted soon

Cristal Delivery created value by building a limited portfolio of innovative nanomedicines. Commercialization will take place by out-licensing products to late-stage pharmaceutical companies generating a revenue stream of milestone payments, royalties and reimbursement of costs. The exit strategy is to sell the company to one of its product development partners.

Visit: http://www.cristaldelivery.com
Connect with Cristal Delivery on partnering360^®

Biotech Showcase™ 2013

Cryoport, Inc.
(OTCBB:CYRX)
Country: United States

CryoPort has developed a game changing solution to the challenge of shipping biological materials under frozen storage conditions. Its CryoPort Express™ solution combines a ...

Share this:

Cryoport, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CYRX
Stock exchange: OTCBB
Schedule information will be posted soon

CryoPort has developed a game changing solution to the challenge of shipping biological materials under frozen storage conditions. Its CryoPort Express™ solution combines a state-of-the-art web-portal with a proprietary dry vapor liquid nitrogen container making the logistics of sending biological materials easier and more reliable compared to traditional dry ice methods.

Visit: http://www.cryoport.com
Connect with Cryoport, Inc. on partnering360^®

Biotech Showcase™ 2013

Curemark
Country: United States

Curemark is focused on the treatment of neurological and other diseases by addressing specific pancreatic secretory deficiencies. It’s lead product, CM-AT, is in Phase III d...

Share this:

Curemark

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Curemark is focused on the treatment of neurological and other diseases by addressing specific pancreatic secretory deficiencies. It’s lead product, CM-AT, is in Phase III development for the treatment of the core symptoms of Autism Spectrum Disorder (ASD). Curemark has multiple disease targets including ASD, ADHD, Parkinson's disease and schizophrenia.

Visit: http://www.curemark.com
Connect with Curemark on partnering360^®

Biotech Showcase™ 2013

CytomX Therapeutics
Country: United States

CytomX is a venture backed company developing Probodies™, proteolytically-activated antibodies. Probodies, by the ability to site-direct the activity of antibodies, result ...

Share this:

CytomX Therapeutics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

CytomX is a venture backed company developing Probodies™, proteolytically-activated antibodies. Probodies, by the ability to site-direct the activity of antibodies, result in an improved therapeutic index for validated targets, as well as enable the drugging of targets with broad tissue expression to provide less toxic therapies for cancer and inflammatory diseases.

Visit: http://www.cytomx.com
Connect with CytomX Therapeutics on partnering360^®

Biotech Showcase™ 2013

Cytori Therapeutics, Inc.
(NASDAQ:CYTX)
Country: United States

Cytori provides physicians with medical technologies that harness the potential of adult regenerative cells from adipose tissue. Cytori is primarily focused on selling its Cel...

Share this:

Cytori Therapeutics, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: CYTX
Stock exchange: NASDAQ
Schedule information will be posted soon

Cytori provides physicians with medical technologies that harness the potential of adult regenerative cells from adipose tissue. Cytori is primarily focused on selling its Celution® System family of medical devices for soft tissue repair in the EU and Asia, and pursuing our applications in cardiovascular disease.

Visit: http://www.cytori.com
Connect with Cytori Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Cytori Therapeutics, Inc.
(NASDAQ:CYTX)
Country: United States

Cytori provides physicians with medical technologies that harness the potential of adult regenerative cells from adipose tissue. Cytori is primarily focused on selling its Cel...

Share this:

Cytori Therapeutics, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: CYTX
Stock exchange: NASDAQ
Schedule information will be posted soon

Visit: http://www.cytori.com
Connect with Cytori Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

CytRx Corporation
(NASDAQ:CYTR )
Country: United States

CytRx has three clinical development programs in oncology. Following tumor shrinkage in a Phase Ib/II trial, CytRx started a Phase IIb trial with INNO-206 for soft tissue sar...

Share this:

CytRx Corporation

Track: Public
Country: United States
Ownership: Public
Ticker: CYTR
Stock exchange: NASDAQ
Schedule information will be posted soon

CytRx has three clinical development programs in oncology. Following tumor shrinkage in a Phase Ib/II trial, CytRx started a Phase IIb trial with INNO-206 for soft tissue sarcomas. Tamibarotene is in a Phase IIb trial in advanced lung cancer. Lastly, CytRx recently completed the bafetinib Phase II trial in B-CLL.

Visit: http://www.cytrx.com
Connect with CytRx Corporation on partnering360^®

Biotech Showcase™ 2013

Debiopharm SA
Country: Switzerland

Debiopharm Group is a financially independent global biopharmaceutical group of companies based in Switzerland. Debiopharm develops prescription drugs targeting unmet medical ...

Share this:

Debiopharm SA

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Debiopharm Group is a financially independent global biopharmaceutical group of companies based in Switzerland. Debiopharm develops prescription drugs targeting unmet medical needs. It in-licenses and develops promising drug candidates. The developed drugs are out-licensed to pharmaceutical partners for commercialisation. Debiopharm is active in companion diagnostics and personalised medicine.

Visit: http://www.debiopharm.com
Connect with Debiopharm SA on partnering360^®

Biotech Showcase™ 2013

Delenex Therapeutics
Country: Switzerland

Delenex seeks to revolutionize antibody treatments in immuno-inflammation by offering safer, topically-administered MAb compounds for chronic diseases, and fast-acting, fast-c...

Share this:

Delenex Therapeutics

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Delenex seeks to revolutionize antibody treatments in immuno-inflammation by offering safer, topically-administered MAb compounds for chronic diseases, and fast-acting, fast-clearing biologics for acute inflammatory pathologies. Delenex has a strong pipeline of proprietary PENTRA® antibodies and will deliver proof of concept in three clinical trials in the second half of 2012.

Visit: http://www.delenex.com
Connect with Delenex Therapeutics on partnering360^®

Biotech Showcase™ 2013

Dendreon
(NASDAQ:DNDN)
Country: United States

Share this:

Dendreon

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: DNDN
Stock exchange: NASDAQ
Schedule information will be posted soon

No information entered

Visit: http://www.dendreon.com
Connect with Dendreon on partnering360^®

Biotech Showcase™ 2013

DiagnoCure, Inc
(TSE:CUR)
Country: Canada

DiagnoCure is a life sciences company that develops and commercializes high-value cancer diagnostic tests. Using the most advanced technology and knowledge base in genomic sci...

Share this:

DiagnoCure, Inc

Track: Public
Country: Canada
Ownership: Public
Ticker: CUR
Stock exchange: TSE
Schedule information will be posted soon

DiagnoCure is a life sciences company that develops and commercializes high-value cancer diagnostic tests. Using the most advanced technology and knowledge base in genomic science, DiagnoCure develops molecular diagnostic tests for cancer patients that answer key clinical questions, providing physicians with the most accurate information possible to make personalized treatment decisions.

Visit: http://www.diagnocure.com
Connect with DiagnoCure, Inc on partnering360^®

Biotech Showcase™ 2013

DLVR Therapeutics, Inc.
Country: Canada

DLVR offers a differentiated nanoparticle that mimics natural HDL biology and allows direct delivery of payload to the cytoplasm through the receptor SR-B1, avoiding degradati...

Share this:

DLVR Therapeutics, Inc.

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

DLVR offers a differentiated nanoparticle that mimics natural HDL biology and allows direct delivery of payload to the cytoplasm through the receptor SR-B1, avoiding degradation. SR-B1 is significantly upregulated in several solid tumors including breast, prostate and colon. DLVR is developing novel formulations of chemotherapeutic drugs and seeking partnerships for siRNA delivery.

Visit: http://www.dlvrtherapeutics.ca
Connect with DLVR Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Domainex
Country: United Kingdom

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focused and integrated appr...

Share this:

Domainex

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focused and integrated approach to medicinal and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes.

Visit: http://www.domainex.co.uk
Connect with Domainex on partnering360^®

Biotech Showcase™ 2013

e-Therapeutics plc
(LON:ETX)
Country: United Kingdom

e-Therapeutics (AIM: ETX) pioneered and exploits network pharmacology as a drug discovery platform. The company is advancing four drugs in the clinic, in oncology, infection a...

Share this:

e-Therapeutics plc

Track: Public
Country: United Kingdom
Ownership: Public
Ticker: ETX
Stock exchange: LON
Schedule information will be posted soon

e-Therapeutics (AIM: ETX) pioneered and exploits network pharmacology as a drug discovery platform. The company is advancing four drugs in the clinic, in oncology, infection and psychiatry, and plans to partner these after mid-phase trials. New discovery projects at Oxford are focused in oncology and degenerative diseases.

Visit: http://www.etherapeutics.co.uk
Connect with e-Therapeutics plc on partnering360^®

Biotech Showcase™ 2013

Echo Therapeutics, Inc.
(NASDAQ:ECTE)
Country: United States

Echo Therapeutics is a transdermal medical device company with deep expertise in advanced skin permeation technology. Echo is developing its Prelude® SkinPrep System as a pla...

Share this:

Echo Therapeutics, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: ECTE
Stock exchange: NASDAQ
Schedule information will be posted soon

Echo Therapeutics is a transdermal medical device company with deep expertise in advanced skin permeation technology. Echo is developing its Prelude® SkinPrep System as a platform technology to allow for significantly enhanced skin permeation that will enable both needle-free drug delivery and analyte extraction.

Visit: http://www.echotx.com
Connect with Echo Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Elusys Therapeutics, Inc.
Country: United States

Elusys, in partnership with the US government since the anthrax attacks of 2001, pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the treatme...

Share this:

Elusys Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Elusys, in partnership with the US government since the anthrax attacks of 2001, pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the treatment of individuals exposed to anthrax. Anthim®, is in late-stage development with near term revenue expected from government procurement. The company is currently well funded.

Visit: http://www.elusys.com
Connect with Elusys Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Enterome Bioscience
Country: France

Enterome, a personalized medicine company, is developing drugs and biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition...

Share this:

Enterome Bioscience

Track: Private
Country: France
Ownership: Private
Schedule information will be posted soon

Enterome, a personalized medicine company, is developing drugs and biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine. Enterome’s technology is based on the most advanced and clinically validated biomarker platform to establish quantitative description of gut microbiota and correlations with disease phenotypes.

Visit: http://www.enterome.com
Connect with Enterome Bioscience on partnering360^®

Biotech Showcase™ 2013

EpiCept Corporation
(NASDAQ:EPCT)
Country: United States

EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management.

Share this:

EpiCept Corporation

Track: Public
Country: United States
Ownership: Public
Ticker: EPCT
Stock exchange: NASDAQ
Schedule information will be posted soon

EpiCept is a specialty pharmaceutical company that focuses on fulfilling unmet medical needs in cancer treatment and pain management.

Visit: http://www.epicept.com
Connect with EpiCept Corporation on partnering360^®

Biotech Showcase™ 2013

Epinex Diagnostics, Inc.
Country: United States

Epinex aims to shift the standard of care for diagnosing and monitoring diabetes and prediabetes (a $26 billion market) using a patented, rapid,monthly test that addresses the...

Share this:

Epinex Diagnostics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Epinex aims to shift the standard of care for diagnosing and monitoring diabetes and prediabetes (a $26 billion market) using a patented, rapid,monthly test that addresses the unmet needs of 95% of diabetics.Company requires $15 million to commercialize and launch it flagship product in the US and abroad.

Visit: http://www.epinex.com
Connect with Epinex Diagnostics, Inc. on partnering360^®

Biotech Showcase™ 2013

Etubics Corp.
Country: United States

Etubics Corporation has developed a next generation adenovirus vector platform for immunotherapy and preventative vaccines. The benefits of Etubics Platform are: safety; thoro...

Share this:

Etubics Corp.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Etubics Corporation has developed a next generation adenovirus vector platform for immunotherapy and preventative vaccines. The benefits of Etubics Platform are: safety; thoroughly studied with Phase I/IIa human data for colon cancer immunotherapy trial; overcomes pre-existing Ad5 immunity allowing for cell mediated immune response; rapid development and diverse product opportunities.

Visit: http://www.etubics.com

Biotech Showcase™ 2013

Evofem
Country: United States

Evofem (San Diego) is a privately held company committed to advancing women’s sexual and reproductive health The Company’s candidate microbicide, Amphora, is in a Phase I...

Share this:

Evofem

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Evofem (San Diego) is a privately held company committed to advancing women’s sexual and reproductive health The Company’s candidate microbicide, Amphora, is in a Phase III contraceptive trial. Additionally, the Company is marketing Softcup™, a novel feminine hygeine product. The company is also advancing drug candidates for pain management. To date $100M has been raised including over $30M from the founders. In addition, the Company has benefitted from government grants of over $250M.

Visit: http://www.wave3trial.com

Biotech Showcase™ 2013

Evozym Biologics
Country: United States

Evozym develops improved proteins and enzymes rapidly and inexpensively using a computational platform of proprietary algorithms and databases. Its approach is combined with a...

Share this:

Evozym Biologics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Evozym develops improved proteins and enzymes rapidly and inexpensively using a computational platform of proprietary algorithms and databases. Its approach is combined with a customized synthetic biology pipeline to work on a limitless range of biological products and results yield transformational improvements that change the economic paradigm in biotechnology and biomedicine.

Visit: http://www.evozym.com
Connect with Evozym Biologics on partnering360^®

Biotech Showcase™ 2013

Exact Sciences Corporation
(NASDAQ:EXAS)
Country: United States

Exact Sciences, a molecular diagnostics company focused on colorectal cancer, has exclusive intellectual property protecting its non-invasive, molecular screening technology f...

Share this:

Exact Sciences Corporation

Track: Public
Country: United States
Ownership: Public
Ticker: EXAS
Stock exchange: NASDAQ
Schedule information will be posted soon

Exact Sciences, a molecular diagnostics company focused on colorectal cancer, has exclusive intellectual property protecting its non-invasive, molecular screening technology for the early detection of colorectal cancer. Stool-based DNA (sDNA) technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force.

Visit: http://www.exactsciences.com
Connect with Exact Sciences Corporation on partnering360^®

Biotech Showcase™ 2013

FluGen, Inc.
Country: United States

FluGen is driving the combination of intradermal delivery and vaccine development. This combination will generate superior returns to investors by improving efficacy and con...

Share this:

FluGen, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

FluGen is driving the combination of intradermal delivery and vaccine development. This combination will generate superior returns to investors by improving efficacy and convenience in large and underserved patient populations such as the elderly, the immune compromised and those at risk from pandemic influenza infection.

Visit: http://www.flugen.com
Connect with FluGen, Inc. on partnering360^®

Biotech Showcase™ 2013

Galena Biopharma
(NASDAQ:GALE)
Country: United States

Galena, a company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, recently presented the trial desi...

Share this:

Galena Biopharma

Track: Public
Country: United States
Ownership: Public
Ticker: GALE
Stock exchange: NASDAQ
Schedule information will be posted soon

Galena, a company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, recently presented the trial design for the upcoming Phase II combination trial with NeuVax™ (E75 plus GM-CSF) and Herceptin® (trastuzumab; Genentech/Roche) at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Visit: http://www.galenabiopharma.com
Connect with Galena Biopharma on partnering360^®

Biotech Showcase™ 2013

GENFIT
(EURONEXT:ALGFT)
Country: France

GENFIT’s product, GFT505, is a ready for Phase IIb drug candidate set to become a first-in-class product for unmet medical needs in the diabetes complications area including...

Share this:

GENFIT

Track: Public
Country: France
Ownership: Public
Ticker: ALGFT
Stock exchange: EURONEXT
Schedule information will be posted soon

GENFIT’s product, GFT505, is a ready for Phase IIb drug candidate set to become a first-in-class product for unmet medical needs in the diabetes complications area including NAFLD/NASH. GENFIT seeks investors to fund the late-stage clinical development and support the optimal progress & value of the product before its licensing.

Visit: http://www.genfit.com
Connect with GENFIT on partnering360^®

Biotech Showcase™ 2013

Genocea Biosciences, Inc.
Country: United States

Genocea develops a new vaccine class using a revolutionary discovery platform. Its pipeline, built in ~3 years, consists of 5 potential blockbusters addressing major unmet ne...

Share this:

Genocea Biosciences, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Genocea develops a new vaccine class using a revolutionary discovery platform. Its pipeline, built in ~3 years, consists of 5 potential blockbusters addressing major unmet needs. Genocea has preclinical PoC for 4 programs and in the next 2 years, seeks human PoC in two programs: HSV-2 (therapeutic) and Pneumococcus.

Visit: http://www.genocea.com
Connect with Genocea Biosciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Genomic Expression
Country: United States

Genomic Expression’s technology integrates intelligent target filtering with sequencing short reads on a small chip and can be implemented without added laboratory infrastru...

Share this:

Genomic Expression

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Genomic Expression’s technology integrates intelligent target filtering with sequencing short reads on a small chip and can be implemented without added laboratory infrastructure expense. It makes the process of developing diagnostics more efficient in linking specific drugs to an individual, saving up to $20 million in pre-clinical biomarker signature development.

Visit: http://www.genomicexpression.com
Connect with Genomic Expression on partnering360^®

Biotech Showcase™ 2013

GenSpera, Inc.
(OTCBB:GNSZ)
Country: United States

GenSpera is developing its lead anti-cancer agent, G-202, for a range of solid tumors. Historically, such drugs with positive Phase II clinical data have had asset values appr...

Share this:

GenSpera, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: GNSZ
Stock exchange: OTCBB
Schedule information will be posted soon

GenSpera is developing its lead anti-cancer agent, G-202, for a range of solid tumors. Historically, such drugs with positive Phase II clinical data have had asset values approximating USD 1 billion. GenSpera expects to generate positive Phase II data with G-202 by second half of 2013.

Visit: http://www.genspera.com/
Connect with GenSpera, Inc. on partnering360^®

Biotech Showcase™ 2013

GenturaDx
Country: United States

GenturaDx is focused on making molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instr...

Share this:

GenturaDx

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

GenturaDx is focused on making molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals circumventing long-standing barriers of costs, automation and performance.

Visit: http://www.genturadx.com
Connect with GenturaDx on partnering360^®

Biotech Showcase™ 2013

GlycoMimetics, Inc.
Country: United States

GlycoMimetics is applying its specialized chemistry platform to develop first in class drug candidates focusing on rare diseases and cancer. The company’s Phase II sickle ce...

Share this:

GlycoMimetics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

GlycoMimetics is applying its specialized chemistry platform to develop first in class drug candidates focusing on rare diseases and cancer. The company’s Phase II sickle cell drug is partnered with Pfizer. Other compounds in our pipeline are being developed as targeted cancer therapies, with significant clinical and commercial opportunities.

Visit: http://www.glycomimetics.com
Connect with GlycoMimetics, Inc. on partnering360^®

Biotech Showcase™ 2013

GlycoVaxyn AG
Country: Switzerland

GlycoVaxyn is dedicated to the development of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technolog...

Share this:

GlycoVaxyn AG

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

GlycoVaxyn is dedicated to the development of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technology.

Visit: http://www.glycovaxyn.com
Connect with GlycoVaxyn AG on partnering360^®

Biotech Showcase™ 2013

GMS Biotech
Country: United States

GMS is commercializing its core technology, which reduces multiple gene content into an inexpensive microarray test that can be performed directly on raw samples. For 2012, GM...

Share this:

GMS Biotech

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

GMS is commercializing its core technology, which reduces multiple gene content into an inexpensive microarray test that can be performed directly on raw samples. For 2012, GMS will launch its “HLA-Chip” into the transplantation and stem cell therapy markets: the first of a pipeline of such “raw sample genotyping” tests.

Visit: http://www.gmsbiotech.com
Connect with GMS Biotech on partnering360^®

Biotech Showcase™ 2013

Harvard Biosciences
Country: United States

Share this:

Harvard Biosciences

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker:
Stock exchange:
Schedule information will be posted soon

No information entered

Visit: http://www.harvardbioscience.com

Biotech Showcase™ 2013

Hawaii Biotech
Country: United States

Hawaii Biotech, Inc. (HBI) is focused on the research and development of vaccines for established and emerging infectious diseases.

Share this:

Hawaii Biotech

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Hawaii Biotech, Inc. (HBI) is focused on the research and development of vaccines for established and emerging infectious diseases.

Visit: http://www.hibiotech.com
Connect with Hawaii Biotech on partnering360^®

Biotech Showcase™ 2013

Healthpoint Biotherapeutics
Country: United States

HEALTHPOINT BIOTHERAPEUTICS is uniquely committed to advancing the science and innovation of wound care. Its unparalleled experience and devotion keep HEALTHPOINT BIOTHERAPEUT...

Share this:

Healthpoint Biotherapeutics

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

HEALTHPOINT BIOTHERAPEUTICS is uniquely committed to advancing the science and innovation of wound care. Its unparalleled experience and devotion keep HEALTHPOINT BIOTHERAPEUTICS at the forefront in the research, development, and marketing of wound care biotechnology that enhances the body’s natural ability to heal.

Visit: http://www.healthpointbio.com
Connect with Healthpoint Biotherapeutics on partnering360^®

Biotech Showcase™ 2013

Hepregen Corporation
Country: United States

Hepregen’s mission is to translate the value of its HepatoPacTM platform to improve the safety and efficacy of drugs in development with greater economic efficiency and sign...

Share this:

Hepregen Corporation

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Hepregen’s mission is to translate the value of its HepatoPacTM platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients’ lives. HepatoPacTM is a high fidelity, micro-engineered, long term in vitro liver model which closely mimics in vivo functionality.

Visit: http://www.hepregen.com
Connect with Hepregen Corporation on partnering360^®

Biotech Showcase™ 2013

Ikaria, Inc.
Country: United States

Ikaria, Inc.'s lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included i...

Share this:

Ikaria, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Ikaria, Inc.'s lead product is INOtherapy®, an all-inclusive offering of drug product, services and technologies. INOMAX® (nitric oxide) for inhalation, the drug included in the INOtherapy offering, is the only FDA approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants.

Visit: http://www.ikaria.com
Connect with Ikaria, Inc. on partnering360^®

Biotech Showcase™ 2013

Immudyne, Inc.
(OTCBB:IMMD)
Country: United States

Immudyne is revenue generating, profitable, debt free, and has 24 million shares outstanding. Immudyne makes immune system enhancing products, for oral and/or topical use: **a...

Share this:

Immudyne, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: IMMD
Stock exchange: OTCBB
Schedule information will be posted soon

Immudyne is revenue generating, profitable, debt free, and has 24 million shares outstanding. Immudyne makes immune system enhancing products, for oral and/or topical use: **all natural, derived from yeast (notably the purest) **protected by numerous patents/proprietary know how ***Clinical evidence ****Pharmaceutical, Topical/Aesthetic dermatological, and Nutraceutical *****stable and reliable

Visit: http://www.immudyne.com
Connect with Immudyne, Inc. on partnering360^®

Biotech Showcase™ 2013

Immune Targeting Systems (ITS) Ltd.
Country: United Kingdom

ITS is seeking to raise a EUR 18-20 million Series-B funding to expedite its universal Hepatitis-B therapeutic vaccine through phase-Ib, lead optimize an oncology indication a...

Share this:

Immune Targeting Systems (ITS) Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

ITS is seeking to raise a EUR 18-20 million Series-B funding to expedite its universal Hepatitis-B therapeutic vaccine through phase-Ib, lead optimize an oncology indication and provide a commercialization runway while seeking a commercialization partner. ITS's lead investors, the Novartis Venture Fund, HealthCap and Truffle Capital, will support this round.

Visit: http://www.its-innovation.com
Connect with Immune Targeting Systems (ITS) Ltd. on partnering360^®

Biotech Showcase™ 2013

ImmunoCellular Therapeutics Ltd.
(OTCBB:IMUC)
Country: United States

ImmunoCellular is developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. It...

Share this:

ImmunoCellular Therapeutics Ltd.

Track: Public
Country: United States
Ownership: Public
Ticker: IMUC
Stock exchange: OTCBB
Schedule information will be posted soon

ImmunoCellular is developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Its lead product is currently in a multi-center, randomized and double blinded phase II clinical trial for glioblastoma.

Visit: http://www.imuc.com
Connect with ImmunoCellular Therapeutics Ltd. on partnering360^®

Biotech Showcase™ 2013

Immunocore Ltd.
Country: United Kingdom

Immunocore has developed a potentially disruptive biologic platform that addresses the fundamental limitation of antibodies; namely, the lack of targets. Immunocore’s rich p...

Share this:

Immunocore Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Immunocore has developed a potentially disruptive biologic platform that addresses the fundamental limitation of antibodies; namely, the lack of targets. Immunocore’s rich pipeline of oncology drugs, the most advanced of which is in the clinic in both the UK and US is expected to benefit imminently from clinical validation.

Visit: http://www.immunocore.com
Connect with Immunocore Ltd. on partnering360^®

Biotech Showcase™ 2013

ImmunoGenetix
Country: United States

ImmunoGenetix Therapeutics, Inc. is a privately held biotechnology company developing advanced DNA immunotherapies for HIV infection. The company’s lead product candidate, G...

Share this:

ImmunoGenetix

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

ImmunoGenetix Therapeutics, Inc. is a privately held biotechnology company developing advanced DNA immunotherapies for HIV infection. The company’s lead product candidate, GenePro™, is a DNA therapeutic construct that yields high levels of gene expression and non-infectious HIV protein production, inducing HIV specific CD8+ memory cells similar to Elite Controllers/LTNP.

Visit: http://www.immunogenetix.com
Connect with ImmunoGenetix on partnering360^®

Biotech Showcase™ 2013

Immunome, Inc.
Country: United States

Immunome is a start-up biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune sys...

Share this:

Immunome, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Immunome is a start-up biopharmaceutical company with a patented native, human antibody platform which enables us to harness the natural curative power of the human immune system. We are using this game-changing technology to develop novel therapies and diagnostics for diseases which currently have no or inadequate treatment options.

Visit: http://www.immunomeinc.com
Connect with Immunome, Inc. on partnering360^®

Biotech Showcase™ 2013

Immunomic Therapeutics, Inc.
Country: United States

Immunomic Therapeutics, Inc. (ITI) is a clinical stage biotechnology company with exceptional patented science for application to vaccines and vaccine immunotherapy. LAMP-vax�...

Share this:

Immunomic Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Immunomic Therapeutics, Inc. (ITI) is a clinical stage biotechnology company with exceptional patented science for application to vaccines and vaccine immunotherapy. LAMP-vax™ significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies.

Visit: http://www.immunomix.com
Connect with Immunomic Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Immunovaccine, Inc.
(TSX-V:IMV)
Country: Canada

Immunovaccine is a vaccine development company focused on commercialization of its DepoVax™ vaccine delivery platform and novel vaccine candidates. Immunovaccine continues t...

Share this:

Immunovaccine, Inc.

Track: Public
Country: Canada
Ownership: Public
Ticker: IMV
Stock exchange: TSX-V
Schedule information will be posted soon

Immunovaccine is a vaccine development company focused on commercialization of its DepoVax™ vaccine delivery platform and novel vaccine candidates. Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines.

Visit: http://www.imvaccine.com
Connect with Immunovaccine, Inc. on partnering360^®

Biotech Showcase™ 2013

Incozen Therapeutics
Country: India

Incozen's mission is to discover and develop medicines for chronic diseases on behalf of Rhizen Pharmaceuticals. Focusing on Oncology, Immuno-inflammation and Metabolic disord...

Share this:

Incozen Therapeutics

Track: Private
Country: India
Ownership: Private
Schedule information will be posted soon

Incozen's mission is to discover and develop medicines for chronic diseases on behalf of Rhizen Pharmaceuticals. Focusing on Oncology, Immuno-inflammation and Metabolic disorders, our targets are selected keeping in mind their potential for clinical and commercial success. The company’s model focuses on taking programs up to PoC and then partnering globally.

Visit: http://www.incozen.com
Connect with Incozen Therapeutics on partnering360^®

Biotech Showcase™ 2013

InflammaGen Therapeutics
Country: United States

InflammaGen Therapeutics is focused on the diagnosis, prevention and treatment of Multiple Organ Failure (MOF) as a result of acute shock, a leading cause of US in-hospital de...

Share this:

InflammaGen Therapeutics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

InflammaGen Therapeutics is focused on the diagnosis, prevention and treatment of Multiple Organ Failure (MOF) as a result of acute shock, a leading cause of US in-hospital deaths. InflammaGen Shok-Pak, is a drug/delivery technology designed to prevent the onset of MOF. Ex-USA human experience supports pre-clinical results in two animals.

Visit: http://www.igenrx.com
Connect with InflammaGen Therapeutics on partnering360^®

Biotech Showcase™ 2013

Innate Immunotherapeutics
Country: New Zealand

Innate Immunotherapeutics has a drug candidate in NMSS supported Phase 2 trials for secondary progressive multiple sclerosis. The candidate has previously been used ‘compass...

Share this:

Innate Immunotherapeutics

Track: Private
Country: New Zealand
Ownership: Private
Schedule information will be posted soon

Innate Immunotherapeutics has a drug candidate in NMSS supported Phase 2 trials for secondary progressive multiple sclerosis. The candidate has previously been used ‘compassionately’ to treat a small group of patients with SPMS in NZ. Significant treatment related improvements in MS related signs & symptoms have been observed.

Visit: http://www.innateimmunotherapeutics.com/

Biotech Showcase™ 2013

Inovio Pharmaceuticals Inc.
(AMEX:INO)
Country: United States

Inovio is revolutionizing vaccines to fight cancers and challenging infectious diseases. Its SynCon® vaccines to universally protect against known and newly emergent pathogen...

Share this:

Inovio Pharmaceuticals Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: INO
Stock exchange: AMEX
Schedule information will be posted soon

Inovio is revolutionizing vaccines to fight cancers and challenging infectious diseases. Its SynCon® vaccines to universally protect against known and newly emergent pathogen strains, combined with its proprietary electroporation delivery, have generated best-in-class immune responses with a favorable safety profile in humans. Phase II studies include cervical dysplasia, leukemia and HCV.

Visit: http://www.inovio.com
Connect with Inovio Pharmaceuticals Inc. on partnering360^®

Biotech Showcase™ 2013

Integrated Magnetic Systems Ltd.
Country: United Kingdom

Integrated Magnetic Systems’s unique nanoparticle technology - magnetic proteins -- all-biological nanoparticles are fusion proteins comprised of a binding portion and a mag...

Share this:

Integrated Magnetic Systems Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Integrated Magnetic Systems’s unique nanoparticle technology - magnetic proteins -- all-biological nanoparticles are fusion proteins comprised of a binding portion and a magnetic portion. The binding portion defines the specificity of the molecule while the magnetic portion defines the utility of the molecule.

Visit: http://www.integratedmagnetics.co.uk
Connect with Integrated Magnetic Systems Ltd. on partnering360^®

Biotech Showcase™ 2013

IntelGenx Technologies Corp.
(IGX:TSX)
Country: Canada

IntelGenx is a rapidly growing high value driven company that focuses on an aggressive product development initiative that targets unmet market needs. IntelGenx leverages its ...

Share this:

IntelGenx Technologies Corp.

Track: Public
Country: Canada
Ownership: Public
Ticker: TSX
Stock exchange: IGX
Schedule information will be posted soon

IntelGenx is a rapidly growing high value driven company that focuses on an aggressive product development initiative that targets unmet market needs. IntelGenx leverages its proprietary delivery technologies to add real therapeutic value to existing therapies in the global space.”

Visit: http://www.intelgenx.com
Connect with IntelGenx Technologies Corp. on partnering360^®

Biotech Showcase™ 2013

IntelliCell BioSciences, Inc.

Share this:

IntelliCell BioSciences, Inc.

Track: Public
Ownership: Public
Ticker:
Stock exchange:
Schedule information will be posted soon

No information entered

Visit: http://www.intellicellbiosciences.com
Connect with IntelliCell BioSciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Intellipharmaceutics International, Inc.
(NASDAQ :IPCI)
Country: Canada

Intellipharmaceutics specializes in the research, development and manufacture of novel and generic controlled-release drugs. Its patented technology platform can be applied to...

Share this:

Intellipharmaceutics International, Inc.

Track: Public
Country: Canada
Ownership: Public
Ticker: IPCI
Stock exchange: NASDAQ
Schedule information will be posted soon

Intellipharmaceutics specializes in the research, development and manufacture of novel and generic controlled-release drugs. Its patented technology platform can be applied to the development of a wide range of pharmaceuticals. Intellipharmaceutics has a pipeline of products in various stages of development, including six ANDAs under review by the FDA.

Visit: http://www.intellipharmaceutics.com
Connect with Intellipharmaceutics International, Inc. on partnering360^®

Biotech Showcase™ 2013

Interleukin Genetics, Inc.
(OTCQB:ILIU)
Country: United States

Interleukin Genetics develops and markets SNP-based, genetic tests under the Inherent Health® and PST® brands. The tests empower individuals to prevent certain chronic condi...

Share this:

Interleukin Genetics, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: ILIU
Stock exchange: OTCQB
Schedule information will be posted soon

Interleukin Genetics develops and markets SNP-based, genetic tests under the Inherent Health® and PST® brands. The tests empower individuals to prevent certain chronic conditions and manage their existing health with clear, actionable guidance. Interleukin Genetics has expertise in research and genetic panel development for metabolic and inflammation based conditions.

Visit: http://www.ilgenetics.com
Connect with Interleukin Genetics, Inc. on partnering360^®

Biotech Showcase™ 2013

InVasc Therapeutics, Inc.
Country: United States

InVasc is developing its lead product for chronic kidney disease, a huge healthcare market segment. This patent protected combination of two approved products has already dem...

Share this:

InVasc Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

InVasc is developing its lead product for chronic kidney disease, a huge healthcare market segment. This patent protected combination of two approved products has already demonstrated strong positive effects in a P.O.C. study in hypertensive diabetic patients. The InVasc pipeline with novel NCE’s approaching clinical development addresses cardiometabolic diseases.

Visit: http://www.invasctherapeutics.com
Connect with InVasc Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

InVivo Therapeutics Corp.
(OTCBB:NVIV)
Country: United States

InVivo is developing biopolymer medical devices for treatment of spinal cord injuries (SCI) and other nervous system conditions. InVivo demonstrated groundbreaking results in ...

Share this:

InVivo Therapeutics Corp.

Track: Public
Country: United States
Ownership: Public
Ticker: NVIV
Stock exchange: OTCBB
Schedule information will be posted soon

InVivo is developing biopolymer medical devices for treatment of spinal cord injuries (SCI) and other nervous system conditions. InVivo demonstrated groundbreaking results in non-human primate studies and expects human trials for their first acute SCI technology in 2012. The market for this product is estimated to be greater than USD 10 billion.

Visit: http://www.invivotherapeutics.com
Connect with InVivo Therapeutics Corp. on partnering360^®

Biotech Showcase™ 2013

IPQ Analytics LLC
Country: United States

IPQ Analytics, LLC provides risk assessment solutions and decision analytics to constituents in life science and healthcare. The company’s solutions enable customers to Iden...

Share this:

IPQ Analytics LLC

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

IPQ Analytics, LLC provides risk assessment solutions and decision analytics to constituents in life science and healthcare. The company’s solutions enable customers to Identify, Prioritize and Quantify new knowledge opportunities and associated risk within the clinical, molecular and commercial domains. IPQ Analytics helps customers to make better-informed decisions earlier.

Visit: http://www.ipqanalytics.com
Connect with IPQ Analytics LLC on partnering360^®

Biotech Showcase™ 2013

ISTO Technologies, Inc.
Country: United States

ISTO Technologies is an orthobiologics company developing innovative cartilage and bone products for spinal therapy and sports medicine indications. ISTO’s strategic focus ...

Share this:

ISTO Technologies, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

ISTO Technologies is an orthobiologics company developing innovative cartilage and bone products for spinal therapy and sports medicine indications. ISTO’s strategic focus is on the development of its ground-breaking platform technology for cartilage regeneration and commercialization of its novel biomaterial platform technology through a unique product that supports bone formation in spinal fusion applications.

Visit: http://www.istotech.com/
Connect with ISTO Technologies, Inc. on partnering360^®

Biotech Showcase™ 2013

Jennerex Biotherapeutics
Country: United States

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. T...

Share this:

Jennerex Biotherapeutics

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594 has shown objective tumor activity, a survival benefit and a strong safety profile in clinical trials and is now in a Phase IIb clinical trial.

Visit: http://www.jennerex.com
Connect with Jennerex Biotherapeutics on partnering360^®

Biotech Showcase™ 2013

Kalos Therapeutics, Inc.
Country: United States

Kalos Therapeutics is an emerging drug development company with the exclusive patent to develop the ANP (Atrial Natriuretic Peptide) family of peptides as a new mechanism for ...

Share this:

Kalos Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Kalos Therapeutics is an emerging drug development company with the exclusive patent to develop the ANP (Atrial Natriuretic Peptide) family of peptides as a new mechanism for the treatment of cancer and other hyperproliferative diseases, which include a new approach to treating AMD with a topical eye drop.

Visit: http://www.kalostpx.com

Biotech Showcase™ 2013

Kenta Biotech Ltd.
Country: Switzerland

Kenta’s pipeline is based on its proprietary technology platform MabIgX. Therapeutic leads include human monoclonal antibodies against some of the most serious hospital path...

Share this:

Kenta Biotech Ltd.

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Kenta’s pipeline is based on its proprietary technology platform MabIgX. Therapeutic leads include human monoclonal antibodies against some of the most serious hospital pathogens including Pseudomonas aeruginosa (PA), Staphylococcus aureus (SA) and Acinetobacter baumannii (AB). Kenta’s pipeline products address the high cost/value market segment of hospital acquired infections.

Visit: http://www.kentabiotech.com
Connect with Kenta Biotech Ltd. on partnering360^®

Biotech Showcase™ 2013

KineMed, Inc.
Country: United States

KineMed’s decision relevant information guides pharma R&D. Its Translational Biomarker Platform pinpoints the function of thousands of proteins, all in a drop of blood, capt...

Share this:

KineMed, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

KineMed’s decision relevant information guides pharma R&D. Its Translational Biomarker Platform pinpoints the function of thousands of proteins, all in a drop of blood, capturing causal process driving disease progression, and predicting clinical outcomes. KineMed successfully collaborates with leading investigators to enable better medicines and power personalized medicine.

Visit: http://www.kinemed.com
Connect with KineMed, Inc. on partnering360^®

Biotech Showcase™ 2013

Koronis Pharmaceuticals
Country: United States

Koronis Pharmaceuticals, Inc is a privately held biopharmaceutical company developing antiviral therapeutics based on Viral Decay AccelerationTM (VDA) - a pioneering treatment...

Share this:

Koronis Pharmaceuticals

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Koronis Pharmaceuticals, Inc is a privately held biopharmaceutical company developing antiviral therapeutics based on Viral Decay AccelerationTM (VDA) - a pioneering treatment approach that offers the possibility of a new therapeutic paradigm for treating chronic viral infections. The company's lead product candidate is KP-1461 for the treatment of HIV.

Visit: http://www.koronispharma.com
Connect with Koronis Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Laboratorios Alpha San Ignacio Pharma
Country: Spain

Laboratorios Alpha San Ignacio Pharma's objective is to jointly run R&D for assembling Carbon nanotube (CNT) sensor and device technology for system in a package.

Share this:

Laboratorios Alpha San Ignacio Pharma

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Laboratorios Alpha San Ignacio Pharma's objective is to jointly run R&D for assembling Carbon nanotube (CNT) sensor and device technology for system in a package.

Visit: http://www.alphasip.es
Connect with Laboratorios Alpha San Ignacio Pharma on partnering360^®

Biotech Showcase™ 2013

Lentigen Corporation
Country: United States

Lentigen is a diversified biologics company focused on proprietary lentiviral gene delivery technology for the development and commercialization of biotherapeutics and vaccine...

Share this:

Lentigen Corporation

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Lentigen is a diversified biologics company focused on proprietary lentiviral gene delivery technology for the development and commercialization of biotherapeutics and vaccines. A combination of strong academic and corporate collaborations support a robust proprietary pipeline that fuels company growth, while a diversity of funding models and business opportunities mitigates risk.

Visit: http://www.lentigen.com
Connect with Lentigen Corporation on partnering360^®

Biotech Showcase™ 2013

Life Length
Country: Spain

Life Length is the world’s only company able to measure critically short telomeres, a crucial biomarker test for measuring biological age for the public and providing telome...

Share this:

Life Length

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Life Length is the world’s only company able to measure critically short telomeres, a crucial biomarker test for measuring biological age for the public and providing telomere measurements services for drug development and clinical trials to the pharma / biotech industry.

Visit: http://www.lifelength.com
Connect with Life Length on partnering360^®

Biotech Showcase™ 2013

Ligand
(NASDAQ:LGND)
Country: United States

Ligand’s business model is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure to produc...

Share this:

Ligand

Track: Public
Country: United States
Ownership: Public
Ticker: LGND
Stock exchange: NASDAQ
Schedule information will be posted soon

Ligand’s business model is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure to produce a bottom line that supports a sustainably profitable business.

Visit: http://www.ligand.com
Connect with Ligand on partnering360^®

Biotech Showcase™ 2013

Linkage Biosciences
Country: United States

Linkage Biosciences is a molecular diagnostics company focused on products for hematopoietic stem cell and solid organ transplantation. LinkSēq™ is the world’s first HLA ...

Share this:

Linkage Biosciences

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Linkage Biosciences is a molecular diagnostics company focused on products for hematopoietic stem cell and solid organ transplantation. LinkSēq™ is the world’s first HLA typing product using real-time PCR and can be completed in as little as 10 minutes of set-up, with fully automated data analysis.

Visit: http://www.linkagebio.com
Connect with Linkage Biosciences on partnering360^®

Biotech Showcase™ 2013

Lipocine, Inc.
Country: United States

Lipocine, Inc. has licensed the first oral testosterone to Abbott Products and is now developing the first oral progestin for PreTerm Birth and the first oral testosterone for...

Share this:

Lipocine, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Lipocine, Inc. has licensed the first oral testosterone to Abbott Products and is now developing the first oral progestin for PreTerm Birth and the first oral testosterone for Female Sexual Dysfunction, both USD 1 billion plus markets. Also, three 505(b)(2) NDA’s filings for Rx Cough/Cold products within 18 months.

Visit: http://www.lipocine.com
Connect with Lipocine, Inc. on partnering360^®

Biotech Showcase™ 2013

MabVax Therapeutics, Inc.
Country: United States

MabVax is focused on the development of vaccine and antibody based therapies for preventing recurrent cancer. Antibodies directed against selected tumor cell surface antigens ...

Share this:

MabVax Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

MabVax is focused on the development of vaccine and antibody based therapies for preventing recurrent cancer. Antibodies directed against selected tumor cell surface antigens can eradicate free tumor cells and micrometastases that remain after treatment and cause cancer recurrence leading to improved quality of life and prolonging overall survival.

Visit: http://www.mabvax.com
Connect with MabVax Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Madrigal Pharmaceuticals
Country: United States

Madrigal is developing novel pharmaceuticals to treat cardiovascular and metabolic diseases. The portfolio includes a Phase I thyroid hormone receptor beta (THRb) agonist for ...

Share this:

Madrigal Pharmaceuticals

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Madrigal is developing novel pharmaceuticals to treat cardiovascular and metabolic diseases. The portfolio includes a Phase I thyroid hormone receptor beta (THRb) agonist for dyslipidemia/hypercholesterolemia and preclinical DGAT1 inhibitors for diabetes, both licensed from Roche. THRb has the potential to show lipid lowering in Madrigal's upcoming multiple ascending dose study.

Visit: http://www.madrigalpharma.com
Connect with Madrigal Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Marina Biotech, Inc.
(NASDAQ:MRNA)
Country: United States

Marina Biotech has the broadest nucleic acid-based discovery platform in the industry with multiple oligonucleotide therapeutic technologies to modulate un-druggable targets. ...

Share this:

Marina Biotech, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: MRNA
Stock exchange: NASDAQ
Schedule information will be posted soon

Marina Biotech has the broadest nucleic acid-based discovery platform in the industry with multiple oligonucleotide therapeutic technologies to modulate un-druggable targets. This capability mitigates program risk and allows partners to focus on a target, not a technology. Marina’s technologies can be applied in the diagnostics, reagents, agricultural and veterinary fields.

Visit: http://www.marinabio.com/
Connect with Marina Biotech, Inc. on partnering360^®

Biotech Showcase™ 2013

MaxCyte, Inc.
Country: United States

MaxCyte’s scalable cell transfection platform is used by pharmaceutical and biotechnology companies around the world to engineer cells for a wide range of applications, incl...

Share this:

MaxCyte, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

MaxCyte’s scalable cell transfection platform is used by pharmaceutical and biotechnology companies around the world to engineer cells for a wide range of applications, including cell therapy for oncology and other life threatening diseases, cell based assays and high throughput screening for small molecule discovery and development, and antibody, protein, and vaccine production.

Visit: http://www.maxcyte.com
Connect with MaxCyte, Inc. on partnering360^®

Biotech Showcase™ 2013

MBio Diagnostics, Inc.
Country: United States

MBio Diagnostics, Inc. is developing a comprehensive system for point-of-care testing: multiplexed immunoassays, cellular analysis, and nucleic acid detection on a unique plat...

Share this:

MBio Diagnostics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

MBio Diagnostics, Inc. is developing a comprehensive system for point-of-care testing: multiplexed immunoassays, cellular analysis, and nucleic acid detection on a unique platform. MBio’s technology addresses a multi-billion dollar, worldwide market opportunity. Performance has been validated in multiple studies, and over one thousand patient samples. Initial products are approaching launch.

Visit: http://www.mbiodx.com
Connect with MBio Diagnostics, Inc. on partnering360^®

Biotech Showcase™ 2013

MDxHealth
(EURONEXT:MDXH)
Country: United States

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing and companion diagnostics for personalized me...

Share this:

MDxHealth

Track: Public
Country: United States
Ownership: Public
Ticker: MDXH
Stock exchange: EURONEXT
Schedule information will be posted soon

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing and companion diagnostics for personalized medicine. It’s numerous cancer tests are based on epigenetic technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

Visit: http://www.mdxhealth.com
Connect with MDxHealth on partnering360^®

Biotech Showcase™ 2013

Merus
Country: Netherlands

Merus’s MeMo® is a single light chain transgenic mouse for human biospecific antibodies. Features include: *transgenic mouse with single light chain and diverse heavy chain...

Share this:

Merus

Track: Private
Country: Netherlands
Ownership: Private
Schedule information will be posted soon

Merus’s MeMo® is a single light chain transgenic mouse for human biospecific antibodies. Features include: *transgenic mouse with single light chain and diverse heavy chains for biospecific human monoclonal antibodies; *efficient discovery and manufacturing of biospecifics based on natural IgG format; *preclinical pipeline of biospecifics for combination of targets expressed on tumor cells.

Visit: http://www.merus.nl
Connect with Merus on partnering360^®

Biotech Showcase™ 2013

Mesoblast
(ASX:MSB)
Country: Australia

Mesoblast Limited (ASX:MSB) is the world’s leading developer of regenerative medicine. Based on its proprietary adult Mesenchymal Precursor Cell technology, Mesoblast’s l...

Share this:

Mesoblast

Track: Regenerative Medicine
Country: Australia
Ownership: Public
Ticker: MSB
Stock exchange: ASX
Schedule information will be posted soon

Mesoblast Limited (ASX:MSB) is the world’s leading developer of regenerative medicine. Based on its proprietary adult Mesenchymal Precursor Cell technology, Mesoblast’s lead therapeutic products are targeting cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions.

Visit: http://www.mesoblast.com
Connect with Mesoblast on partnering360^®

Biotech Showcase™ 2013

Metabolon, Inc.
Country: United States

Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented metabolomics platform provides a globa...

Share this:

Metabolon, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented metabolomics platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. Our diagnostics pipeline comprises products focused in cancer and metabolism.

Visit: http://www.metabolon.com/
Connect with Metabolon, Inc. on partnering360^®

Biotech Showcase™ 2013

MetaSignal Therapeutics, Inc.
Country: Canada

MetaSignal Therapeutics seeks $ 2.5 million to advance its Hypoxia Drug Development program IND candidate to an approved IND cadidate, plus $3.5 million to complete two phase ...

Share this:

MetaSignal Therapeutics, Inc.

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

MetaSignal Therapeutics seeks $ 2.5 million to advance its Hypoxia Drug Development program IND candidate to an approved IND cadidate, plus $3.5 million to complete two phase I clinical trials. MetaSignal will create value by licensing its proprietary drug compound and development program or by seeking another exit within 36 months.

Visit: http://www.metasignal.ca
Connect with MetaSignal Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Microphama Ltd.
Country: Canada

Micropharma Ltd. is focused on innovation and R&D through POC. The company discovers and develops proprietary live biotherapeutic products for metabolic diseases and out-licen...

Share this:

Microphama Ltd.

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

Micropharma Ltd. is focused on innovation and R&D through POC. The company discovers and develops proprietary live biotherapeutic products for metabolic diseases and out-licenses these products to partners for commercialization in the medical food, consumer healthcare, and biotherapeutics markets. Micropharma is seeking partnerships and growth financing from qualified institutional investors.

Visit: http://www.micropharma.net
Connect with Microphama Ltd. on partnering360^®

Biotech Showcase™ 2013

Miragen Therapeutics, Inc.
Country: United States

MiRagen Therapeutics is a pre-clinical stage biopharmaceutical company founded to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. MicroR...

Share this:

Miragen Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

MiRagen Therapeutics is a pre-clinical stage biopharmaceutical company founded to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. MicroRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. For more information, please visit www.miragentherapeutics.com.

Visit: http://www.miragenrx.com
Connect with Miragen Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Mirimus, Inc.
Country: United States

Mirimus, Inc. engineers the most efficient RNA interference tools for rapid and cost-effective methods of target identification, validation and toxicology assessment in vivo. ...

Share this:

Mirimus, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Mirimus, Inc. engineers the most efficient RNA interference tools for rapid and cost-effective methods of target identification, validation and toxicology assessment in vivo. Our technology offers an attractive approach to streamline preclinical drug discovery research, increase confidence and dramatically reduce attrition rates of compounds entering clinical trials.

Visit: http://www.mirimus.com
Connect with Mirimus, Inc. on partnering360^®

Biotech Showcase™ 2013

Mirna Therapeutics, Inc.
Country: United States

Mirna Therapeutics poised to emerge as the leading company in miRNA-based therapies for cancer. Armed with leading IP portfolio on therapeutic use of key miRNAs in cancer, and...

Share this:

Mirna Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Mirna Therapeutics poised to emerge as the leading company in miRNA-based therapies for cancer. Armed with leading IP portfolio on therapeutic use of key miRNAs in cancer, and tumor growth inhibition demonstrated with multiple miRNAs with multiple delivery technologies, Mirna has a clearly defined path to the clinic.

Visit: http://www.mirnarx.com
Connect with Mirna Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

MSDx, Inc.
Country: United States

MSDx, Inc. is commercializing blood testing products for neurological, autoimmune, and inflammatory disorders. Multiple Sclerosis is the first disease of focus. These products...

Share this:

MSDx, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

MSDx, Inc. is commercializing blood testing products for neurological, autoimmune, and inflammatory disorders. Multiple Sclerosis is the first disease of focus. These products will provide physicians with critical information that aids in monitoring disease progression, tracks response to drug therapy, predicts impending relapses, and facilitates drug development.

Visit: http://www.msdx.co
Connect with MSDx, Inc. on partnering360^®

Biotech Showcase™ 2013

Mucosis BV
Country: Netherlands

Share this:

Mucosis BV

Track: Private
Country: Netherlands
Ownership: Private
Schedule information will be posted soon

No information entered

Visit: http://www.mucosis.com
Connect with Mucosis BV on partnering360^®

Biotech Showcase™ 2013

Mymetics Corp.
(OTCBB:MYMX)
Country: Switzerland

Mymetics is focused on developing innovative preventive vaccines against viruses such as HIV, Respiratory Syncytial Virus, Influenza, Herpes Simplex and Malaria. The company u...

Share this:

Mymetics Corp.

Track: Public
Country: Switzerland
Ownership: Public
Ticker: MYMX
Stock exchange: OTCBB
Schedule information will be posted soon

Mymetics is focused on developing innovative preventive vaccines against viruses such as HIV, Respiratory Syncytial Virus, Influenza, Herpes Simplex and Malaria. The company uses its proprietary virosome platform to develop vaccines that preferably generate a mucosal first line of defense against potential viruses.

Visit: http://www.mymetics.com

Biotech Showcase™ 2013

NanoSight
Country: United Kingdom

NanoSight is profitable and self-financing and has grown at 73% CAGR for six years. Now an opportunity exists for a Pharmaceuticals Company to buy into our unique technology a...

Share this:

NanoSight

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

NanoSight is profitable and self-financing and has grown at 73% CAGR for six years. Now an opportunity exists for a Pharmaceuticals Company to buy into our unique technology and apply it in Personalized Medicine and Companion Diagnostics.

Visit: http://www.nanosight.com
Connect with NanoSight on partnering360^®

Biotech Showcase™ 2013

Nanotherapeutics, Inc.
Country: United States

Nanotherapeutics, Inc. is a specialty pharmaceutical company focused on repurposing known compounds, either through indication expansion or reformulation, for infectious disea...

Share this:

Nanotherapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Nanotherapeutics, Inc. is a specialty pharmaceutical company focused on repurposing known compounds, either through indication expansion or reformulation, for infectious diseases, neurology and oncology while utilizing proprietary drug delivery and manufacturing technologies in a highly efficient capital model with organic growth through product sales, government contracts and partnering acquired compounds.

Visit: http://www.nanotherapeutics.com
Connect with Nanotherapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

Natrix Separations
Country: Canada

Natrix Separations technology delivers step-change improvements in the way biopharmaceuticals are harvested and purified. The technology enables biomanufacturers to dramatical...

Share this:

Natrix Separations

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

Natrix Separations technology delivers step-change improvements in the way biopharmaceuticals are harvested and purified. The technology enables biomanufacturers to dramatically improve asset utilization by overcoming downstream bottlenecks that limit the operation of existing plants. The single-use disposable technology also enables the development of next-generation biomanufacturing plants, which were previously constrained by available technologies.

Visit: http://www.natrixseparatioons.com
Connect with Natrix Separations on partnering360^®

Biotech Showcase™ 2013

Navidea Biopharmaceuticals (formerly Neoprobe Corp.)
(AMEX:NAVB)
Country: United States

Navidea Biopharmaceuticals is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three r...

Share this:

Navidea Biopharmaceuticals (formerly Neoprobe Corp.)

Track: Public
Country: United States
Ownership: Public
Ticker: NAVB
Stock exchange: AMEX
Schedule information will be posted soon

Navidea Biopharmaceuticals is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM CR – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care.

Visit: http://www.neoprobe.com
Connect with Navidea Biopharmaceuticals (formerly Neoprobe Corp.) on partnering360^®

Biotech Showcase™ 2013

NeoGenomics, Inc.
(OTCBB:NGNM)
Country: United States

NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in molecular genetics testing for cancer, the fastest growing segment of the laboratory ...

Share this:

NeoGenomics, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: NGNM
Stock exchange: OTCBB
Schedule information will be posted soon

NeoGenomics is a high-complexity CLIA–certified clinical laboratory that specializes in molecular genetics testing for cancer, the fastest growing segment of the laboratory industry. NeoGenomics reported USD 11.3 million of revenue in Q3 11, a 30% YoY increase, and 40% of the incremental revenue was incremental profit.

Visit: http://www.neogenomics.com
Connect with NeoGenomics, Inc. on partnering360^®

Biotech Showcase™ 2013

NeoStem, Inc. (Amorcyte)
(AMEX:NBS)
Country: United States

NeoStem’s Amorcyte subsidiary is developing a cell therapy for the treatment of cardiovascular disease and its lead compound is poised to commence enrollment in a Phase II t...

Share this:

NeoStem, Inc. (Amorcyte)

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: NBS
Stock exchange: AMEX
Schedule information will be posted soon

NeoStem’s Amorcyte subsidiary is developing a cell therapy for the treatment of cardiovascular disease and its lead compound is poised to commence enrollment in a Phase II trial for the preservation of heart function after a heart attack.

Visit: http://www.neostem.com
Connect with NeoStem, Inc. (Amorcyte) on partnering360^®

Biotech Showcase™ 2013

Neuralstem
Country: United States

Share this:

Neuralstem

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker:
Stock exchange:
Schedule information will be posted soon

No information entered

Visit: http://www.neuralstem.com
Connect with Neuralstem on partnering360^®

Biotech Showcase™ 2013

NeuroGeneration, Inc.
Country: United States

NeuroGeneration has developed innovative technologies to regenerate central nervous tissue using adult derived neural progenitor stem cells obtained directly from the patient....

Share this:

NeuroGeneration, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

NeuroGeneration has developed innovative technologies to regenerate central nervous tissue using adult derived neural progenitor stem cells obtained directly from the patient. Once grown “in vitro” and developed with the company’s proprietary technologies, healthy neuronal cells are then re-implanted to successfully repair and repopulate deficient motor circuitry.

Visit: http://www.neurogeneration.com
Connect with NeuroGeneration, Inc. on partnering360^®

Biotech Showcase™ 2013

Neurotez, Inc.
Country: United States

Neurotez’s primary product is a pre-IND opportunity involving the development of a recombinant version of the naturally occurring protein Leptin as a hormone replacement the...

Share this:

Neurotez, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Neurotez’s primary product is a pre-IND opportunity involving the development of a recombinant version of the naturally occurring protein Leptin as a hormone replacement therapy for Alzheimer's disease. A compelling combination of cell culture, transgenic animal model, epidemiological, and anecdotal human data point to the potential utility of this approach.

Visit: http://www.neurotez.com
Connect with Neurotez, Inc. on partnering360^®

Biotech Showcase™ 2013

NewGen Therapeutics, Inc.
Country: United States

NewGen Therapeutics is developing targeted small molecule therapeutics for the treatment of cancer. The firm has three late pre-clinical development candidates: (i) NT-113 I...

Share this:

NewGen Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

NewGen Therapeutics is developing targeted small molecule therapeutics for the treatment of cancer. The firm has three late pre-clinical development candidates: (i) NT-113 Irreversible pan-erbB inhibitor (ii) NT-004 EGFR/Her2 dual inhibitor (iii) NT-125 PARP inhibitor; proven scientific and business leadership; and a focus on promising validated targets; Leveraged medicinal chemistry.

Visit: http://www.newgenther.com/
Connect with NewGen Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

NexImmune, Inc.
Country: United States

NexImmune, Inc. holds an exclusive to the Artificial IMmune (AIM™) technology from Johns Hopkins University, a nanotechnology with which the immune system is guided by a syn...

Share this:

NexImmune, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Private
Schedule information will be posted soon

NexImmune, Inc. holds an exclusive to the Artificial IMmune (AIM™) technology from Johns Hopkins University, a nanotechnology with which the immune system is guided by a synthetic cell to orchestrate a specific response. NexImmune’s first therapeutic, for melanoma, will be ready for testing in humans by 2013.

Visit: http://www.neximmune.com/
Connect with NexImmune, Inc. on partnering360^®

Biotech Showcase™ 2013

NuPathe
(NASDAQ:PATH)
Country: United States

NuPathe is an emerging biopharmaceutical company focused on innovative neuroscience with a late-stage asset for the treatment of migraine, addressing a large patient populatio...

Share this:

NuPathe

Track: Public
Country: United States
Ownership: Public
Ticker: PATH
Stock exchange: NASDAQ
Schedule information will be posted soon

NuPathe is an emerging biopharmaceutical company focused on innovative neuroscience with a late-stage asset for the treatment of migraine, addressing a large patient population. NuPathe’s SmartRelief technology allows the company to capitalize on the expanding global transdermal market by potentially opening new classes of medications for delivery through the skin.

Visit: http://www.nupathe.com
Connect with NuPathe on partnering360^®

Biotech Showcase™ 2013

NX PharmaGen, Inc.
Country: United States

NX PharmaGen is developing molecular diagnostic tests for prenatal and oncology indications using proteomic biomarkers within exosomes shed into patients’ blood as a “liq...

Share this:

NX PharmaGen, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

NX PharmaGen is developing molecular diagnostic tests for prenatal and oncology indications using proteomic biomarkers within exosomes shed into patients’ blood as a “liquid biopsy.” Human studies in preterm birth and solid tumors (lung, ovarian, brain, head/neck) have demonstrated an ability to assess disease risk/detection, subtyping, and drug receptor functionality.

Visit: http://www.nxpharmagen.com
Connect with NX PharmaGen, Inc. on partnering360^®

Biotech Showcase™ 2013

Oculus Innovative Sciences, Inc.
(NASDAQ:OCLS)
Country: United States

Oculus is pioneering innovative solutions in multiple markets including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized prod...

Share this:

Oculus Innovative Sciences, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: OCLS
Stock exchange: NASDAQ
Schedule information will be posted soon

Oculus is pioneering innovative solutions in multiple markets including dermatology, oral care, surgical, wound care, animal healthcare and others, and has commercialized products in the United States, Europe, India, China and Mexico and select Middle East countries.

Visit: http://www.oculusis.com
Connect with Oculus Innovative Sciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Ohr Pharmaceutical, Inc.
(OTCBB:OHRP)
Country: United States

Ohr Pharmaceutical, Inc. is dedicated to the clinical development of new drugs for underserved therapeutic needs. The company is focused on two lead products: Squalamine eye d...

Share this:

Ohr Pharmaceutical, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: OHRP
Stock exchange: OTCBB
Schedule information will be posted soon

Ohr Pharmaceutical, Inc. is dedicated to the clinical development of new drugs for underserved therapeutic needs. The company is focused on two lead products: Squalamine eye drops for the treatment of the wet age-related macular degeneration, and OHR/AVR118 for treating cancer cachexia, currently being investigated in a Phase II trial.

Visit: http://www.ohrpharmaceutical.com
Connect with Ohr Pharmaceutical, Inc. on partnering360^®

Biotech Showcase™ 2013

Omnia Molecular
Country: Spain

Omnia Molecular designs and develops novel anti-infectives with our proprietary platform technology targeted at difficult-to-treat infections: nosocomial gram+/-, Mycosis and ...

Share this:

Omnia Molecular

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Omnia Molecular designs and develops novel anti-infectives with our proprietary platform technology targeted at difficult-to-treat infections: nosocomial gram+/-, Mycosis and Tuberculosis. Omnia's business model is to partner with pharma industry from the proof of concept stage and out-license drug candidates at clinical proof of efficacy (phase IIa).

Visit: http://www.omniamol.com
Connect with Omnia Molecular on partnering360^®

Biotech Showcase™ 2013

OncBioMune
Country: United States

OncBioMune, LLC, is a six year old company, which has concentrated its efforts on translational research of targeted cancer therapies and therapeutic cancer vaccines. The co...

Share this:

OncBioMune

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

OncBioMune, LLC, is a six year old company, which has concentrated its efforts on translational research of targeted cancer therapies and therapeutic cancer vaccines. The company’s lead product, Prostatac (a therapeutic prostate cancer vaccine), will be entering a fully funded phase I clinical trial in 2012 at the UCSD Moore’s Cancer Center.

Visit: http://www.oncbiomune.com
Connect with OncBioMune on partnering360^®

Biotech Showcase™ 2013

Oncolix, Inc.
Country: United States

Oncolix is a clinical-stage biotechnology company. The company is currently conducting a Phase I trial for the indication of ovarian cancer. The drug (Prolanta) is a therapeut...

Share this:

Oncolix, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Oncolix is a clinical-stage biotechnology company. The company is currently conducting a Phase I trial for the indication of ovarian cancer. The drug (Prolanta) is a therapeutic protein with a novel mechanism of action.

Visit: http://www.oncolixbio.com
Connect with Oncolix, Inc. on partnering360^®

Biotech Showcase™ 2013

Onconova Therapeutics, Inc.
Country: United States

Onconova is currently exploring financing towards NDA filing for lead product Estybon® (aka rigosertib sodium/ON 01910.Na), which is now in a pivotal Phase III trial under an...

Share this:

Onconova Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Onconova is currently exploring financing towards NDA filing for lead product Estybon® (aka rigosertib sodium/ON 01910.Na), which is now in a pivotal Phase III trial under an SPA for refractory MDS patients, and in Phase III trials for pancreatic cancer and low-risk MDS.

Visit: http://www.onconova.com
Connect with Onconova Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

OncoSec Medical, Inc.
(OTCBB:ONCS)
Country: United States

Oncosec’s ElectroOncology anti-cancer therapies are based on a proprietary electroporation delivery system used to deliver either an immunotherapeutic or chemotherapeutic ag...

Share this:

OncoSec Medical, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: ONCS
Stock exchange: OTCBB
Schedule information will be posted soon

Oncosec’s ElectroOncology anti-cancer therapies are based on a proprietary electroporation delivery system used to deliver either an immunotherapeutic or chemotherapeutic agent. OncoSec’s clinical pipeline includes three Phase II trials in melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, as well as Phase III-IV experience in head and neck cancer.

Visit: http://www.oncosec.com
Connect with OncoSec Medical, Inc. on partnering360^®

Biotech Showcase™ 2013

Oragenics
(OTCBB:ORNI)
Country: United States

Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The company's proprietary products Evora® and ProBiora3® are curr...

Share this:

Oragenics

Track: Public
Country: United States
Ownership: Public
Ticker: ORNI
Stock exchange: OTCBB
Schedule information will be posted soon

Oragenics is a leading nutraceutical company focused on oral care probiotics for humans and companion pets. The company's proprietary products Evora® and ProBiora3® are currently sold in over 20 countries. In addition, Oragenics has a robust pipeline of therapeutic products targeting infectious disease.

Visit: http://www.oragenics.com
Connect with Oragenics on partnering360^®

Biotech Showcase™ 2013

Organovo, Inc.
Country: United States

Organovo intends to introduce a paradigm shift in the approach to the generation of human tissues by creation of constructs in 3D that have the potential to replicate native h...

Share this:

Organovo, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker:
Stock exchange:
Schedule information will be posted soon

Organovo intends to introduce a paradigm shift in the approach to the generation of human tissues by creation of constructs in 3D that have the potential to replicate native human biology. Creation of 3D tissues, can accelerate the drug discovery process, improve toxicology testing, and allow for creation of transplant tissues.

Visit: http://www.organovo.com
Connect with Organovo, Inc. on partnering360^®

Biotech Showcase™ 2013

Ovamed GmbH
Country: Germany

Ovamed has developed a highly efficient, natural novelty to treat autoimmune diseases. It is the first therapy ever without side effects of clinical relevance. Optimum compl...

Share this:

Ovamed GmbH

Track: Private
Country: Germany
Ownership: Private
Schedule information will be posted soon

Ovamed has developed a highly efficient, natural novelty to treat autoimmune diseases. It is the first therapy ever without side effects of clinical relevance. Optimum compliance is ensured by oral administration. Successful clinical studies are available on multiple sclerosis and inflammatory bowel disease.

Visit: http://www.ovamed.org
Connect with Ovamed GmbH on partnering360^®

Biotech Showcase™ 2013

Oxford BioMedica plc
(LON:OXB)
Country: United Kingdom

Gene therapy and immunotherapy have enormous potential to benefit the lives of patients. Oxford BioMedica is one of the leading companies in this field. We have established a ...

Share this:

Oxford BioMedica plc

Track: Public
Country: United Kingdom
Ownership: Public
Ticker: OXB
Stock exchange: LON
Schedule information will be posted soon

Gene therapy and immunotherapy have enormous potential to benefit the lives of patients. Oxford BioMedica is one of the leading companies in this field. We have established a platform of highly innovative technologies to deliver genes that code for therapeutic proteins or induce an immune response.

Visit: http://www.oxfordbiomedica.co.uk
Connect with Oxford BioMedica plc on partnering360^®

Biotech Showcase™ 2013

Pacific Edge
(NZX:PEB)
Country: New Zealand

Pacific Edge is a cancer diagnostics company with a patented, denovo, accurate, molecular diagnostic product for early detection and monitoring of bladder cancer, Cxbladder®....

Share this:

Pacific Edge

Track: Public
Country: New Zealand
Ownership: Public
Ticker: PEB
Stock exchange: NZX
Schedule information will be posted soon

Pacific Edge is a cancer diagnostics company with a patented, denovo, accurate, molecular diagnostic product for early detection and monitoring of bladder cancer, Cxbladder®. International expansion, launched in Australia, NZ, Spain, now US. US market estimated annual USD 150 million. Next, colorectal cancer prognostic product market ready. Portfolio of patents pending globally.

Visit: http://www.peblnz.com
Connect with Pacific Edge on partnering360^®

Biotech Showcase™ 2013

Palau Pharma
Country: Spain

Palau is focused on research and development for medicines that are designed to address the unmet needs of patients suffering from inflammatory and autoimmune diseases. A spi...

Share this:

Palau Pharma

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Palau is focused on research and development for medicines that are designed to address the unmet needs of patients suffering from inflammatory and autoimmune diseases. A spin-out of Grupo Uriach's R&D Unit, it was capitalized by five external investors: Caixa Catalunya, Caja Duero, Najeti Capital, Andosins Capital and senior management.

Visit: http://www.palaupharma.com
Connect with Palau Pharma on partnering360^®

Biotech Showcase™ 2013

Palobiofarma
Country: Spain

Palobiofarma's strong and diversified pipeline comprises: PBF-680: A novel, potent adenosine A1 antagonist as a first in class compound for oral asthma treatment. PBF-509: A...

Share this:

Palobiofarma

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

Palobiofarma's strong and diversified pipeline comprises: PBF-680: A novel, potent adenosine A1 antagonist as a first in class compound for oral asthma treatment. PBF-509: A novel, potent adenosine A2a antagonist as a best in class compound for the PD treatment. Looking to close a series A financing of 8 Mio USD.

Visit: http://www.palobiofarma.com
Connect with Palobiofarma on partnering360^®

Biotech Showcase™ 2013

Peregerine Pharmaceuticals
(NASDAQ:PPHM)
Country: United States

Peregrine is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The ...

Share this:

Peregerine Pharmaceuticals

Track: Public
Country: United States
Ownership: Public
Ticker: PPHM
Stock exchange: NASDAQ
Schedule information will be posted soon

Peregrine is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®.

Visit: http://www.peregrineinc.com

Biotech Showcase™ 2013

PharmAbcine, Inc.
Country: South Korea

PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resource...

Share this:

PharmAbcine, Inc.

Track: Private
Country: South Korea
Ownership: Private
Schedule information will be posted soon

PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.

Visit: http://www.pharmabcine.com
Connect with PharmAbcine, Inc. on partnering360^®

Biotech Showcase™ 2013

PharmacoFore, Inc.
Country: United States

PharmacoFore, a privately-held biopharmaceutical company, has developed a resilient business model for creating long-term value by generating lower risk, commercially relevant...

Share this:

PharmacoFore, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

PharmacoFore, a privately-held biopharmaceutical company, has developed a resilient business model for creating long-term value by generating lower risk, commercially relevant new chemical entities quickly and efficiently. We carefully select programs wherein (i) mechanisms-of-action are known and (ii) human proof-of-concept can be achieved early in clinicaltrials.

Visit: http://www.pharmacofore.com
Connect with PharmacoFore, Inc. on partnering360^®

Biotech Showcase™ 2013

PlantForm Corporation
Country: Canada

PlantForm is a Canadian company with a novel, plant-based technology platform designed to produce therapeutic antibody drugs at ultra-low cost. Our first product will be a su...

Share this:

PlantForm Corporation

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

PlantForm is a Canadian company with a novel, plant-based technology platform designed to produce therapeutic antibody drugs at ultra-low cost. Our first product will be a subsequent-entry biologic directly comparable to the breast cancer drug Herceptin. Reducing this cost is essential to help more patients get the medicine they need.

Visit: http://www.plantformcorp.com
Connect with PlantForm Corporation on partnering360^®

Biotech Showcase™ 2013

PolyBatics
Country: New Zealand

PolyBatics has developed a technology for the in vivo production of protein displaying polymer beads. These beads have demonstrated the potential to fundamentally change how m...

Share this:

PolyBatics

Track: Private
Country: New Zealand
Ownership: Private
Schedule information will be posted soon

PolyBatics has developed a technology for the in vivo production of protein displaying polymer beads. These beads have demonstrated the potential to fundamentally change how monoclonal antibodies and other therapeutic proteins are manufactured. The technology represents the first disposable option for bioprocessing operations including chromatography and biosynthesis.

Visit: http://www.polybatics.com
Connect with PolyBatics on partnering360^®

Biotech Showcase™ 2013

PolyTherics Ltd.
Country: United Kingdom

PolyTherics offers site-specific conjugation technologies for PK/PD optimisation and the creation of bispecific products and protein drug conjugates. The TheraPEG™ technolog...

Share this:

PolyTherics Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

PolyTherics offers site-specific conjugation technologies for PK/PD optimisation and the creation of bispecific products and protein drug conjugates. The TheraPEG™ technology has been successfully applied to create long-acting forms of interferon β for treatment of multiple sclerosis and Factor IX for hemophilia B. Antibody-drug conjugates are expanding the field of application for the company’s technologies.

Visit: http://www.polytherics.com
Connect with PolyTherics Ltd. on partnering360^®

Biotech Showcase™ 2013

Pressure BioSciences, Inc.
(NASDAQ:PBIO)
Country: United States

Pressure BioSciences markets products based on pressure cycling technology (PCT). PCT uses alternating cycles of pressure to prepare samples for analysis, including the safe, ...

Share this:

Pressure BioSciences, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: PBIO
Stock exchange: NASDAQ
Schedule information will be posted soon

Pressure BioSciences markets products based on pressure cycling technology (PCT). PCT uses alternating cycles of pressure to prepare samples for analysis, including the safe, rapid, and reproducible extraction of DNA/RNA/proteins/small molecules from a wide variety of samples. Approximately 140 laboratories use the PCT Platform for mass spec and other downstream applications.

Visit: http://www.pressurebiosciences.com
Connect with Pressure BioSciences, Inc. on partnering360^®

Biotech Showcase™ 2013

Prima BioMed
Country: Australia

Share this:

Prima BioMed

Track: Regenerative Medicine
Country: Australia
Ownership: Private
Schedule information will be posted soon

No information entered

Visit: http://www.primabiomed.com.au
Connect with Prima BioMed on partnering360^®

Biotech Showcase™ 2013

ProFibrix
Country: Netherlands

ProFibrix is starting Phase III with Fibrocaps in 2012 after a highly successful Phase II program. Fibrocaps is a novel ready-to-use powder based fibrin sealant that is room t...

Share this:

ProFibrix

Track: Private
Country: Netherlands
Ownership: Private
Schedule information will be posted soon

ProFibrix is starting Phase III with Fibrocaps in 2012 after a highly successful Phase II program. Fibrocaps is a novel ready-to-use powder based fibrin sealant that is room temperature stable and developed for use by surgeons as a topical hemostat and sealant.

Visit: http://www.profibrix.com
Connect with ProFibrix on partnering360^®

Biotech Showcase™ 2013

ProMetic Life Sciences, Inc.
(TSE:PLI)
Country: Canada

ProMetic Life Sciences, Inc. is a global biopharmaceutical business, comprised of a group of companies developing technologies to bring safer, cost-effective and more convenie...

Share this:

ProMetic Life Sciences, Inc.

Track: Public
Country: Canada
Ownership: Public
Ticker: PLI
Stock exchange: TSE
Schedule information will be posted soon

ProMetic Life Sciences, Inc. is a global biopharmaceutical business, comprised of a group of companies developing technologies to bring safer, cost-effective and more convenient pharmaceutical products to market than those already available. ProMetic’s has two distinct operating segments; Protein Technologies and Therapeutics, supported by a Head Office in Laval, Canada.

Visit: http://www.prometic.com
Connect with ProMetic Life Sciences, Inc. on partnering360^®

Biotech Showcase™ 2013

ProtAffin AG
Country: Austria

ProtAffin AG is a European biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, using its p...

Share this:

ProtAffin AG

Track: Private
Country: Austria
Ownership: Private
Schedule information will be posted soon

ProtAffin AG is a European biotechnology company developing a novel class of next-generation biopharmaceuticals for respiratory disease, inflammation and oncology, using its proprietary CellJammer® discovery technology. Its lead, PA401, an IL-8 decoy in preclinical development for COPD, has demonstrated outstanding preclinical pharmacology and will enter Phase I studies in 2Q2012.

Visit: http://www.protaffin.com
Connect with ProtAffin AG on partnering360^®

Biotech Showcase™ 2013

Protagonist Therapeutics, Inc.
Country: United States

Protagonist Therapeutics is a peptide & peptidomimetic therapeutics company pursuing the discovery and development of disulfide rich peptides (DRPs) as new chemical entities (...

Share this:

Protagonist Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Protagonist Therapeutics is a peptide & peptidomimetic therapeutics company pursuing the discovery and development of disulfide rich peptides (DRPs) as new chemical entities (NCEs) against those Targets for which: 1) Small molecules (SMs) or antibodies (Abs) do not offer a good product and 2) well differentiated and superior ‘alternatives to antibodies’.

Visit: http://www.protagonist-inc.com
Connect with Protagonist Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

PsiOxus Therapeutics Ltd.
Country: United Kingdom

PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company. Our lead program, MT-102, is a phase II Anabolic Catabolic Transforming Agent with an exce...

Share this:

PsiOxus Therapeutics Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

PsiOxus Therapeutics Ltd is an Oxford based development stage biotechnology company. Our lead program, MT-102, is a phase II Anabolic Catabolic Transforming Agent with an excellent profile in cachexia and sarcopenia. Our second clinical stage asset is ColoAd1, a potent, highly selective and systemically available oncolytic virus for metastatic cancer.

Visit: http://www.psioxus.com
Connect with PsiOxus Therapeutics Ltd. on partnering360^®

Biotech Showcase™ 2013

Q Therapeutics, Inc
Country: United States

Q Therapeutics has harnessed the power of stem cells to treat debilitating neurodegenerative diseases, encompassing ALS, MS, spinal cord injury, Parkinson’s and Alzheimer’...

Share this:

Q Therapeutics, Inc

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker:
Stock exchange:
Schedule information will be posted soon

Q Therapeutics has harnessed the power of stem cells to treat debilitating neurodegenerative diseases, encompassing ALS, MS, spinal cord injury, Parkinson’s and Alzheimer’s diseases. 15 patents provide barrier to others. Q-Cells® function as ‘mini-factories’ to repair neurons, addressing a multi-billion dollar market opportunity for which traditional drugs have failed.

Visit: http://www.qthera.com
Connect with Q Therapeutics, Inc on partnering360^®

Biotech Showcase™ 2013

ReNeuron Group plc
(LON:RENE)
Country: United Kingdom

ReNeuron is clinical-stage stem cell business whose objective is the development of novel stem cell therapies. ReNeuron has used its unique stem cell technologies to develop...

Share this:

ReNeuron Group plc

Track: Regenerative Medicine
Country: United Kingdom
Ownership: Public
Ticker: RENE
Stock exchange: LON
Schedule information will be posted soon

ReNeuron is clinical-stage stem cell business whose objective is the development of novel stem cell therapies. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.

Visit: http://www.reneuron.com
Connect with ReNeuron Group plc on partnering360^®

Biotech Showcase™ 2013

Repros Therapeutics (RPRX)
(NASDAQ:RPRX)
Country: United States

Repros Therapeutics Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Share this:

Repros Therapeutics (RPRX)

Track: Public
Country: United States
Ownership: Public
Ticker: RPRX
Stock exchange: NASDAQ
Schedule information will be posted soon

Repros Therapeutics Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders.

Visit: http://www.reprosrx.com
Connect with Repros Therapeutics (RPRX) on partnering360^®

Biotech Showcase™ 2013

Reset Therapeutics, Inc.
Country: United States

Reset Therapeutics was formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body’s network of internal molecular clocks. T...

Share this:

Reset Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Reset Therapeutics was formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body’s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status.

Biotech Showcase™ 2013

Resverlogix Corp.
(TSE:RVX)
Country: Canada

Resverlogix is developing novel therapies for global medical markets with significant unmet needs. We are developing novel small molecules that enhance ApoA-I production to tr...

Share this:

Resverlogix Corp.

Track: Public
Country: Canada
Ownership: Public
Ticker: RVX
Stock exchange: TSE
Schedule information will be posted soon

Resverlogix is developing novel therapies for global medical markets with significant unmet needs. We are developing novel small molecules that enhance ApoA-I production to treat Atherosclerosis, Acute Coronary Syndrome, Alzheimer’s disease and Autoimmune diseases. Lead drug RVX-208 is in two Phase IIb clinical trials led by Cleveland Clinic.

Visit: http://www.resverlogix.com
Connect with Resverlogix Corp. on partnering360^®

Biotech Showcase™ 2013

Ritter Pharmaceuticals, Inc.
Country: United States

Ritter Pharmaceuticals is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on ...

Share this:

Ritter Pharmaceuticals, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Ritter Pharmaceuticals is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. RP-G28 has completed Phase II trials and has the potential to become the first FDA-approved treatment for lactose intolerance.

Visit: http://www.ritterpharma.com
Connect with Ritter Pharmaceuticals, Inc. on partnering360^®

Biotech Showcase™ 2013

Saladax Biomedical, Inc.
Country: United States

Saladax Biomedical is a diagnostics company developing and commercializing products for personalized medicine. Our first product, My5-FU™, measures the levels of the chemoth...

Share this:

Saladax Biomedical, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Saladax Biomedical is a diagnostics company developing and commercializing products for personalized medicine. Our first product, My5-FU™, measures the levels of the chemotherapy drug 5-fluorouricil (5-FU) in a patient’s blood. My5-FU has European Conformity (CE) marking and marketing efforts are already underway in the European Union (EU) and other countries.

Visit: http://www.saladax.com
Connect with Saladax Biomedical, Inc. on partnering360^®

Biotech Showcase™ 2013

SALIENT PHARMACEUTICALS
Country: United States

Salient Pharmaceuticals is developing a patent-pending, all-natural compound to address gastrointestinal disorders. A Phase II study is underway for cancer therapy-induced dia...

Share this:

SALIENT PHARMACEUTICALS

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Salient Pharmaceuticals is developing a patent-pending, all-natural compound to address gastrointestinal disorders. A Phase II study is underway for cancer therapy-induced diarrhea and positive pre-clinical data for Clostridium difficile and inflammatory bowel disease applications has been developed. Initial data also indicates the potential for oral mucositis and radiation injury applications.

Visit: http://www.salientpharmaceuticals.com
Connect with SALIENT PHARMACEUTICALS on partnering360^®

Biotech Showcase™ 2013

SanBio
Country: United States

Share this:

SanBio

Track: Regenerative Medicine
Country: United States
Ownership: Regenerative
Schedule information will be posted soon

No information entered

Visit: http://www.san-bio.com
Connect with SanBio on partnering360^®

Biotech Showcase™ 2013

Santhera Pharmaceuticals
(SWX:SANN)
Country: Switzerland

Santhera is a specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of orphan neuromuscular and mi...

Share this:

Santhera Pharmaceuticals

Track: Public
Country: Switzerland
Ownership: Public
Ticker: SANN
Stock exchange: SWX
Schedule information will be posted soon

Santhera is a specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of orphan neuromuscular and mitochondrial diseases, areas of high unmet medical need with no current therapies. Santhera focuses on the development and commercialization of the Catena® franchise in multiple orphan indications.

Visit: http://www.santhera.com
Connect with Santhera Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Savara
Country: United States

Savara is developing a dry powder inhalable form of vancomycin for the treatment of MRSA infection in CF and other high risk patients. Studies show that MRSA shortens survival...

Share this:

Savara

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Savara is developing a dry powder inhalable form of vancomycin for the treatment of MRSA infection in CF and other high risk patients. Studies show that MRSA shortens survival time for CF patients. A Phase 1 trial is successfully completed and a proof-of-concept trial in CF patents is now underway.

Visit: http://www.savarapharma.com
Connect with Savara on partnering360^®

Biotech Showcase™ 2013

Seachaid Pharmaceuticals
Country: United States

Utlizing its novel chemistry and formulation expertise, Seachaid’s pipeline currently includes an oral formulation of cefepime entering phase I, an IV/oral program for a nov...

Share this:

Seachaid Pharmaceuticals

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Utlizing its novel chemistry and formulation expertise, Seachaid’s pipeline currently includes an oral formulation of cefepime entering phase I, an IV/oral program for a novel antifungal in the echinocandin class, and an IV/oral program for a novel MRSA-active glycopeptide. Seachaid owns 100% of its pipeline. Aisling Capital is the founding investor.

Visit: http://www.seachaid.com
Connect with Seachaid Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Selecta Biosciences
Country: United States

Selecta develops a novel class of Synthetic Vaccine Particles (SVP™). This breakthrough technology resolves limitations of today’s biological vaccines in terms of costs, s...

Share this:

Selecta Biosciences

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Selecta develops a novel class of Synthetic Vaccine Particles (SVP™). This breakthrough technology resolves limitations of today’s biological vaccines in terms of costs, speed, storage, efficacy and safety. Selecta’s nicotine vaccine for smoking cessation entered into human clinical trials. Vaccines for cancer, auto-immune and infectious diseases are in pre-clinical development.

Visit: http://www.selectabio.com
Connect with Selecta Biosciences on partnering360^®

Biotech Showcase™ 2013

Selexis SA
Country: Switzerland

Selexis is a profitable life science company with technologies for cell line development and scale-up to manufacturing of therapeutic proteins. With our new innovations in d...

Share this:

Selexis SA

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Selexis is a profitable life science company with technologies for cell line development and scale-up to manufacturing of therapeutic proteins. With our new innovations in drug discovery, Selexis’ SUREtechnology platform improves identification, development and clinical success of novel biotherapeutics while reducing the time and costs associated with drug development.

Visit: http://www.selexis.com
Connect with Selexis SA on partnering360^®

Biotech Showcase™ 2013

Senesco Technologies, Inc.
(AMEX:SNT)
Country: United States

Senesco’s novel, proprietary platform (99 issued patents) can generate multiple product opportunities. Our first therapeutic candidate, SNS01-T, targeted at B-cell cancers, ...

Share this:

Senesco Technologies, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: SNT
Stock exchange: AMEX
Schedule information will be posted soon

Senesco’s novel, proprietary platform (99 issued patents) can generate multiple product opportunities. Our first therapeutic candidate, SNS01-T, targeted at B-cell cancers, is subject of on-going clinical studies in multiple myeloma at the Mayo clinic, which are expected to produce a steady stream of results over the next 12 – 15 months.

Visit: http://www.senesco.com
Connect with Senesco Technologies, Inc. on partnering360^®

Biotech Showcase™ 2013

Sensor Pharma, Inc.
Country: United States

Sensor Pharmaceuticals is a virtual drug discovery and drug development company focused on treatments for metabolic disease. Sensor has several new molecular entities operativ...

Share this:

Sensor Pharma, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Sensor Pharmaceuticals is a virtual drug discovery and drug development company focused on treatments for metabolic disease. Sensor has several new molecular entities operative via MoA's connecting inflammation and metabolic disease. Specifically, GPR120 is a free fatty acid sensor and the likely target of omega fish oils.

Visit: http://no website
Connect with Sensor Pharma, Inc. on partnering360^®

Biotech Showcase™ 2013

Sensorin
Country: United States

Sensorin's molecular electronics system is poised for launch in the existing $1 Billion pH monitoring market. Our first product is a self-calibrating solid state pH sensor for...

Share this:

Sensorin

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Sensorin's molecular electronics system is poised for launch in the existing $1 Billion pH monitoring market. Our first product is a self-calibrating solid state pH sensor for in-line process optimization in multiple industries, among them health care. Our product pipeline of multimodal sensors is enabled by the semiconductor based technology.

Visit: http://www.sensorin.com
Connect with Sensorin on partnering360^®

Biotech Showcase™ 2013

Sequella, Inc.
Country: United States

Sequella, a clinical-stage anti-infectives company, leverages its expertise in infectious diseases, global contacts, and efficient use of capital to identify and develop new d...

Share this:

Sequella, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Sequella, a clinical-stage anti-infectives company, leverages its expertise in infectious diseases, global contacts, and efficient use of capital to identify and develop new drugs for serious life-threatening infections. Sequella has drugs in Phase II clinical trials for TB (Africa) and Helicobacter pylori infections (U.S.) and a commercialization partner in Russia.

Visit: http://www.sequella.com
Connect with Sequella, Inc. on partnering360^®

Biotech Showcase™ 2013

Sernova Corp.
(TSX-V:SVA)
Country: Canada

Sernova is committed to developing and commercializing products which benefit patients with chronic metabolic, neurological, and haematological diseases first product with a f...

Share this:

Sernova Corp.

Track: Public
Country: Canada
Ownership: Public
Ticker: SVA
Stock exchange: TSX-V
Schedule information will be posted soon

Sernova is committed to developing and commercializing products which benefit patients with chronic metabolic, neurological, and haematological diseases first product with a first product focus on diabetes. Sernova has two platform technologies. The first is the Cell Pouch System(TM) an implantable medical device. The second is Sertolin(TM) a cell based technology.

Visit: http://www.sernova.com
Connect with Sernova Corp. on partnering360^®

Biotech Showcase™ 2013

Shield Therapeutics
Country: United Kingdom

Shield Therapeutics, an independent specialty pharmaceutical company focused on late-stage, mineral-derived hospital pharmaceuticals, is currently conducting two pivotal Phase...

Share this:

Shield Therapeutics

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Shield Therapeutics, an independent specialty pharmaceutical company focused on late-stage, mineral-derived hospital pharmaceuticals, is currently conducting two pivotal Phase III studies of ST10, a novel oral iron-based therapy, for the treatment of iron deficiency anaemia in IBD. Shield is well funded by private, corporate and institutional investors.

Visit: http://www.shieldtherapeutics.com
Connect with Shield Therapeutics on partnering360^®

Biotech Showcase™ 2013

Shire Pharmaceuticals (Advanced BioHealing)
Country: United States

Shire is a global specialty biopharmaceuticals company with operations in 28 countries and several medicines available in more than 45 countries. Its Advanced BioHealing divis...

Share this:

Shire Pharmaceuticals (Advanced BioHealing)

Track: Regenerative Medicine
Country: United States
Schedule information will be posted soon

Shire is a global specialty biopharmaceuticals company with operations in 28 countries and several medicines available in more than 45 countries. Its Advanced BioHealing division is focused on Regenerative Medicine. In general, we focus on opportunities that have demonstrated proof of concept, but will review earlier opportunities.

Visit: http://www.shire.com
Connect with Shire Pharmaceuticals (Advanced BioHealing) on partnering360^®

Biotech Showcase™ 2013

Sialix, Inc.
Country: United States

Sialix is a pioneer in glycobiology, specializing in sialic acid research and technology platform solutions. Our mission is to provide pure, more effective biotheraputics thro...

Share this:

Sialix, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Sialix is a pioneer in glycobiology, specializing in sialic acid research and technology platform solutions. Our mission is to provide pure, more effective biotheraputics through the detection and elimination of non-human sialic acid (Neu5Gc or NGNA) that has been linked to chronic inflammation that can lead to disease.

Visit: http://www.sialix.com
Connect with Sialix, Inc. on partnering360^®

Biotech Showcase™ 2013

Siloam Biosciences, Inc.
Country: United States

Share this:

Siloam Biosciences, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

No information entered

Visit: http://www.siloambio.com
Connect with Siloam Biosciences, Inc. on partnering360^®

Biotech Showcase™ 2013

SOM Biotech
Country: Spain

SOM, founded to exploit the re-use of known compounds in new clinical indications. In 20 months, has identified and patented two candidates to be pushed to Phase IIa and anoth...

Share this:

SOM Biotech

Track: Private
Country: Spain
Ownership: Private
Schedule information will be posted soon

SOM, founded to exploit the re-use of known compounds in new clinical indications. In 20 months, has identified and patented two candidates to be pushed to Phase IIa and another back-up with its proprietary discovery engine and an investment of EUR 500,000. This approach potentially offers high returns with managed risk.

Visit: http://www.sombiotech.com
Connect with SOM Biotech on partnering360^®

Biotech Showcase™ 2013

Spinifex Pharmaceuticals Pty, Ltd.
Country: Australia

Spinifex is developing EMA401 as a first in class, oral treatment for neuropathic pain without CNS side effects, initially in patients failing frontline therapy. EMA401 is an ...

Share this:

Spinifex Pharmaceuticals Pty, Ltd.

Track: Private
Country: Australia
Ownership: Private
Schedule information will be posted soon

Spinifex is developing EMA401 as a first in class, oral treatment for neuropathic pain without CNS side effects, initially in patients failing frontline therapy. EMA401 is an antagonist at the angiotensin II type 2 receptor, an novel approach to the treatment of neuropathic pain, which has no overlap with ARBs.

Visit: http://www.spinifexpharma.com.au
Connect with Spinifex Pharmaceuticals Pty, Ltd. on partnering360^®

Biotech Showcase™ 2013

Stellar Biotechnologies, Inc.
(TSX-V::KLH)
Country: United States

Stellar is the world leader in sustainable manufacture of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). KLH is an important immune stimulating and carrier protein that...

Share this:

Stellar Biotechnologies, Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: KLH
Stock exchange: TSX-V:
Schedule information will be posted soon

Stellar is the world leader in sustainable manufacture of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). KLH is an important immune stimulating and carrier protein that is ideal for use in vaccines and diagnostic products, but is sourced from a rare and depleting natural resource, for which Stellar has unique solutions.

Visit: http://www.stellarbiotechnologies.com
Connect with Stellar Biotechnologies, Inc. on partnering360^®

Biotech Showcase™ 2013

StemCells, Inc.
(NASDAQ:STEMD)
Country: United States

StemCells has pioneered the discovery and development of a highly purified population of expandable,bankable, human neural stem cells,HuCNS-SC®,for use in the treatment of in...

Share this:

StemCells, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: STEMD
Stock exchange: NASDAQ
Schedule information will be posted soon

StemCells has pioneered the discovery and development of a highly purified population of expandable,bankable, human neural stem cells,HuCNS-SC®,for use in the treatment of injuries to, and diseases of, the Central Nervous System,including Spinal Cord Injury,Age-Related Macular Degeneration,Myelin Disorders and Alzheimer’s.

Visit: http://www.stemcellsinc.com
Connect with StemCells, Inc. on partnering360^®

Biotech Showcase™ 2013

SuperNova Diagnostics, Inc.
Country: United States

SuperNova Diagnostics®, Inc. is a privately-held, early commercialization-stage diagnostics company that has developed a market-changing technology in the USD 15 billion glob...

Share this:

SuperNova Diagnostics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

SuperNova Diagnostics®, Inc. is a privately-held, early commercialization-stage diagnostics company that has developed a market-changing technology in the USD 15 billion global market for point-of-interest, point-of-care diagnostics. AmpCrystal®, SuperNova’s proprietary diagnostic platform, allows for direct detection of proteins, pathogens and DNA without PCR amplification in versatile and cost-effective product designs.

Visit: http://www.supernovadiagnostics.com
Connect with SuperNova Diagnostics, Inc. on partnering360^®

Biotech Showcase™ 2013

SuviCa
Country: United States

SuviCa, an oncology company, is targeting a unique cellular pathway. Leads are identified utilizing a proprietary assay. The initial clinical candidate is being evaluated fo...

Share this:

SuviCa

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

SuviCa, an oncology company, is targeting a unique cellular pathway. Leads are identified utilizing a proprietary assay. The initial clinical candidate is being evaluated for "fast to market" orphan indications with follow-ons targeting larger patient populations. Business model has versatile exit points. Two compounds are expected in man by 2013.

Visit: http://www.suvica.com
Connect with SuviCa on partnering360^®

Biotech Showcase™ 2013

Symbios Medical Products
Country: United States

Share this:

Symbios Medical Products

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

No information entered

Visit: http://www.symbiosmedical.com
Connect with Symbios Medical Products on partnering360^®

Biotech Showcase™ 2013

Syntaxin Ltd.
Country: United Kingdom

Syntaxin’s strategy is to create value by leveraging its broad expertise in botulinum neurotoxin biology in the discovery and development of a new class of compounds, Target...

Share this:

Syntaxin Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Syntaxin’s strategy is to create value by leveraging its broad expertise in botulinum neurotoxin biology in the discovery and development of a new class of compounds, Targeted Secretion Inhibitors (TSI), that treat disease through selective inhibition of cell secretory pathways.

Visit: http://www.syntaxin.com
Connect with Syntaxin Ltd. on partnering360^®

Biotech Showcase™ 2013

Telormedix SA
Country: Switzerland

Telormedix is focused on targeted immunity and the innate immune system role in treating cancer and autoimmune diseases. The company’s lead product entered a Phase I/II clin...

Share this:

Telormedix SA

Track: Private
Country: Switzerland
Ownership: Private
Schedule information will be posted soon

Telormedix is focused on targeted immunity and the innate immune system role in treating cancer and autoimmune diseases. The company’s lead product entered a Phase I/II clinical study for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC), which will within the next couple of months establish the PoC in humans.

Visit: http://www.telormedix.com
Connect with Telormedix SA on partnering360^®

Biotech Showcase™ 2013

Tengion
(NASDAQ:TNGN)
Country: United States

Tengion's mission is to transform the lives of patients in need of an organ transplant or augmentation by developing autologous neo-organs and tissues that harness the regener...

Share this:

Tengion

Track: Regenerative Medicine
Country: United States
Ownership: Public
Ticker: TNGN
Stock exchange: NASDAQ
Schedule information will be posted soon

Tengion's mission is to transform the lives of patients in need of an organ transplant or augmentation by developing autologous neo-organs and tissues that harness the regenerative power of the patient's own healthy tissue, enabling it to restore vital functions.

Visit: http://www.tengion.com
Connect with Tengion on partnering360^®

Biotech Showcase™ 2013

TiGenix
(EURONEXT:TIG)
Country: Belgium

TiGenix uniquely combines early commercial revenues with a mid- to long-term pipeline of adipose stem cell programs. TiGenix has the world’s most advanced stem cell therapy ...

Share this:

TiGenix

Track: Regenerative Medicine
Country: Belgium
Ownership: Public
Ticker: TIG
Stock exchange: EURONEXT
Schedule information will be posted soon

TiGenix uniquely combines early commercial revenues with a mid- to long-term pipeline of adipose stem cell programs. TiGenix has the world’s most advanced stem cell therapy platform with products in Phase I, II, and III development. The company markets ChondroCelect, the EMA’s only approved cell therapy product, for cartilage repair.

Visit: http://www.tigenix.com
Connect with TiGenix on partnering360^®

Biotech Showcase™ 2013

Tissue Genesis, Inc.
Country: United States

Share this:

Tissue Genesis, Inc.

Track: Regenerative Medicine
Country: United States
Ownership: PRS
Schedule information will be posted soon

No information entered

Visit: http://www.tissuegenesis.com
Connect with Tissue Genesis, Inc. on partnering360^®

Biotech Showcase™ 2013

TONIX Pharmaceuticals
(OTCBB:TNXP)
Country: United States

TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The company targets conditions characterized by significant unmet me...

Share this:

TONIX Pharmaceuticals

Track: Public
Country: United States
Ownership: Public
Ticker: TNXP
Stock exchange: OTCBB
Schedule information will be posted soon

TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. Its most advanced product candidates are TNX-102, for fibromyalgia, and TNX-105 for PTSD.

Visit: http://www.tonixpharma.com
Connect with TONIX Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

Toxikon Corp.
Country: United States

Toxikon is a preclinical contract research organization with over 30 years of diverse product development capabilities and regulatory support, working in 35+ countries and a C...

Share this:

Toxikon Corp.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Toxikon is a preclinical contract research organization with over 30 years of diverse product development capabilities and regulatory support, working in 35+ countries and a CAGR of 12.5% over the last 5 years. It maintains a strong technology position by working with Harvard, MIT and other premier academic/teaching institutions.

Visit: http://www.toxikon.com
Connect with Toxikon Corp. on partnering360^®

Biotech Showcase™ 2013

TRACON Pharmaceuticals
Country: United States

TRACON Pharmaceuticals secured $24.5MM in March 2011 and has since advanced the antibody TRC105, a “Top 10 Oncology Program to Watch”, into eight Phase1b/Phase2 trials in ...

Share this:

TRACON Pharmaceuticals

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

TRACON Pharmaceuticals secured $24.5MM in March 2011 and has since advanced the antibody TRC105, a “Top 10 Oncology Program to Watch”, into eight Phase1b/Phase2 trials in oncology.

Visit: http://www.traconpharma.com
Connect with TRACON Pharmaceuticals on partnering360^®

Biotech Showcase™ 2013

U.S. Preventive Medicine
Country: United States

U.S. Preventive Medicine delivers technology solutions that leverage the power of preventive medicine including The Prevention Plan, an online platform that determines an indi...

Share this:

U.S. Preventive Medicine

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

U.S. Preventive Medicine delivers technology solutions that leverage the power of preventive medicine including The Prevention Plan, an online platform that determines an individual’s health risks and provides a plan to reduce those risks; and Macaw™app, which integrates with The Prevention Plan, other applications and wireless devices.

Visit: http://www.uspreventivemedicine.com

Biotech Showcase™ 2013

Unigene Laboratories
(OTCBB:UGNE)
Country: United States

Unigene is a leader in the design, delivery, manufacture and development of peptide-based therapeutics focused on metabolic disease and inflammation. Unigene plans to generat...

Share this:

Unigene Laboratories

Track: Public
Country: United States
Ownership: Public
Ticker: UGNE
Stock exchange: OTCBB
Schedule information will be posted soon

Unigene is a leader in the design, delivery, manufacture and development of peptide-based therapeutics focused on metabolic disease and inflammation. Unigene plans to generate near-term revenue from feasibility studies and service fees and establish a solid foundation for potential high-value milestones and royalties.

Visit: http://www.unigene.com
Connect with Unigene Laboratories on partnering360^®

Biotech Showcase™ 2013

Valley Fever Solutions
Country: United States

Valley Fever Solutions is developing Nikkomycin Z (NikZ), first of a new class of antifungals. We plan to generate USD 250 million annually under our Orphan Drug designation f...

Share this:

Valley Fever Solutions

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Valley Fever Solutions is developing Nikkomycin Z (NikZ), first of a new class of antifungals. We plan to generate USD 250 million annually under our Orphan Drug designation for treating Valley Fever, which sends 5,000 patients annually to seek serious medical intervention. 100 die. We are studying additional antifungal indications.

Visit: http://www.valleyfeversolutions.com
Connect with Valley Fever Solutions on partnering360^®

Biotech Showcase™ 2013

Vapogenix, Inc.
Country: United States

Vapogenix is creating a new category of analgesics, based on formulated volatile anesthetics, to treat localized pain without the systemic side effects of existing drugs. Its ...

Share this:

Vapogenix, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Vapogenix is creating a new category of analgesics, based on formulated volatile anesthetics, to treat localized pain without the systemic side effects of existing drugs. Its first product is a quick acting topical analgesic that is substantially faster than competing products.

Visit: http://www.vapogenix.com
Connect with Vapogenix, Inc. on partnering360^®

Biotech Showcase™ 2013

VentriNova, Inc.
Country: United States

Share this:

VentriNova, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

No information entered

Biotech Showcase™ 2013

Vicus Therapeutics, LLC
Country: United States

Share this:

Vicus Therapeutics, LLC

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

No information entered

Visit: http://www.vicustherapeutics.com
Connect with Vicus Therapeutics, LLC on partnering360^®

Biotech Showcase™ 2013

Vybion, Inc.
Country: United States

Vybion ProCodeTM Intrabody technology addresses challenging intracellular targets, including protein-protein interactions and epitopes in mutant alleles, and control of dose a...

Share this:

Vybion, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Vybion ProCodeTM Intrabody technology addresses challenging intracellular targets, including protein-protein interactions and epitopes in mutant alleles, and control of dose and affinity to mimic pharmacologically relevant events. Our lead drug is an Intrabody that prevents mutant protein aggregation in accepted cell-based models in Huntington’s, with human trials in 18 months.

Visit: http://www.vybion.com
Connect with Vybion, Inc. on partnering360^®

Biotech Showcase™ 2013

Xalud Therapeutics, Inc.
Country: United States

Xalud Therapeutics is developing novel therapeutics for neuro-inflammatory diseases including neuropathic pain, multiple sclerosis and ALS. Xalud’s lead product, XT-101, ha...

Share this:

Xalud Therapeutics, Inc.

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

Xalud Therapeutics is developing novel therapeutics for neuro-inflammatory diseases including neuropathic pain, multiple sclerosis and ALS. Xalud’s lead product, XT-101, has demonstrated excellent efficacy in gold standard animal models of neuropathic pain. Xalud expects to initiate a Phase I/IIa trial of XT-101 in neuropathic pain patients in 2013.

Visit: http://www.xaludthera.com
Connect with Xalud Therapeutics, Inc. on partnering360^®

Biotech Showcase™ 2013

XBiotech
Country: United States

XBiotech is a biopharmaceutical developer and manufacturer of first-in-class antibody therapies. The company's lead candidate inhibits chronic (sterile) inflammation involved...

Share this:

XBiotech

Track: Private
Country: United States
Ownership: Private
Schedule information will be posted soon

XBiotech is a biopharmaceutical developer and manufacturer of first-in-class antibody therapies. The company's lead candidate inhibits chronic (sterile) inflammation involved in progression of both serious and common diseases. Xbiotech has ongoing clinical trials in dermatology, oncology, diabetes, cachexia and cardiovascular disease. These clinical programs are driving rapid value creation.

Visit: http://www.xbiotech.com
Connect with XBiotech on partnering360^®

Biotech Showcase™ 2013

Xention Ltd.
Country: United Kingdom

Xention is developing potential breakthrough drugs for atrial fibrillation (AF). Xention’s programmes are focused on the exciting new ion channel targets Kv1.5 and IKACh bot...

Share this:

Xention Ltd.

Track: Private
Country: United Kingdom
Ownership: Private
Schedule information will be posted soon

Xention is developing potential breakthrough drugs for atrial fibrillation (AF). Xention’s programmes are focused on the exciting new ion channel targets Kv1.5 and IKACh both of which are expressed only in the atria with the objective of developing atrial-specific therapeutics that maintain normal sinus rhythm .

Visit: http://www.xention.com
Connect with Xention Ltd. on partnering360^®

Biotech Showcase™ 2013

XOMA
(NASDAQ:XOMA)
Country: United States

XOMA’s pipeline includes XOMA 052, a potent anti-IL-1 beta antibody entering Phase III clinical development in Behcet’s uveitis, which has been designated an orphan drug, ...

Share this:

XOMA

Track: Public
Country: United States
Ownership: Public
Ticker: XOMA
Stock exchange: NASDAQ
Schedule information will be posted soon

XOMA’s pipeline includes XOMA 052, a potent anti-IL-1 beta antibody entering Phase III clinical development in Behcet’s uveitis, which has been designated an orphan drug, and has potential for the treatment of a wide range of inflammatory conditions. XOMA has signed a regional development and license agreement with Servier.

Visit: http://www.xoma.com
Connect with XOMA on partnering360^®

Biotech Showcase™ 2013

Zalicus Inc.
(NASDAQ:ZLCS)
Country: United States

Zalicus utilizes its unique drug discovery and development capabilities to develop a pipeline of innovative therapies for the treatment of pain and inflammation. Our unique mi...

Share this:

Zalicus Inc.

Track: Public
Country: United States
Ownership: Public
Ticker: ZLCS
Stock exchange: NASDAQ
Schedule information will be posted soon

Zalicus utilizes its unique drug discovery and development capabilities to develop a pipeline of innovative therapies for the treatment of pain and inflammation. Our unique mix of powerful discovery technologies, novel clinical programs and experienced drug development professionals provide a solid foundation for success.

Visit: http://www.zalicus.com
Connect with Zalicus Inc. on partnering360^®

Biotech Showcase™ 2013

Zymeworks, Inc.
Country: Canada

Zymeworks develops best-in-class protein therapeutics to treat cancer, autoimmune and inflammatory diseases. Zymeworks designs proprietary multi-valent IgG1 antibodies and alt...

Share this:

Zymeworks, Inc.

Track: Private
Country: Canada
Ownership: Private
Schedule information will be posted soon

Zymeworks develops best-in-class protein therapeutics to treat cancer, autoimmune and inflammatory diseases. Zymeworks designs proprietary multi-valent IgG1 antibodies and alternative protein scaffolds with tailored effector function and optimized serum half-life, differentiating itself from competing platforms. In 2011 Zymeworks’ partnered with Merck to develop bi-specific antibody therapeutics using its Azymetric™ platform.

Visit: http://www.zymeworks.com
Connect with Zymeworks, Inc. on partnering360^®

Biotech Showcase™ 2013